





FIG. 1



**FIG. 2**



**FIG. 3**



**FIG. 4**








FIG. 5




**FIG. 6**



**FIG. 7**

**FIG. 8**









FIG. 9



**FIG. 10**



**FIG. 11**



**FIG. 12**






FIG. 13







Fig. 14



**FIG. 15**



**FIG. 16**





FIG. 17



**FIG. 18**






FIG. 19

**A**



**B**



**FIG. 20**









FIG. 21



**FIG. 22**



**FIG. 23**



**FIG. 24**

Query Object	Red	Implication Relationship	Type	Quality	B	In	C	In	S	p	Int	Imp	Exp	Spec	Obs	Exp
Alendronate	245	Osteoarthritis	D	221.60	0.83	0.45	0.63	0.52	0.52	0.52	0.52	0.52	0.52	0.52	4.16	921.57
Alendronate	224	Uremia	CP	201.23	0.81	0.28	0.35	0.47	0.47	0.47	0.47	0.47	0.47	0.47	4.06	816.65
Alendronate	219	end-stage renal disease	CP	195.90	0.81	0.26	0.36	0.46	0.46	0.46	0.46	0.46	0.46	0.46	3.94	771.91
Alendronate	239	Breast carcinoma	CP	215.06	0.83	0.46	0.32	0.50	0.50	0.50	0.50	0.50	0.50	0.50	3.91	841.22
Alendronate	214	Hyperlipidemia	CP	190.28	0.75	0.35	0.27	0.44	0.44	0.44	0.44	0.44	0.44	0.44	3.86	734.64
Alendronate	261	Chronic renal failure	CP	235.87	0.85	0.30	0.52	0.55	0.55	0.55	0.55	0.55	0.55	0.55	3.80	895.70
Alendronate	245	Renal insufficiency	CP	222.06	0.84	0.26	0.41	0.52	0.52	0.52	0.52	0.52	0.52	0.52	3.78	839.29
Alendronate	244	Renal disease	CP	217.90	0.79	0.24	0.36	0.51	0.51	0.51	0.51	0.51	0.51	0.51	3.77	822.33
Alendronate	182	Synovitis	D	162.50	0.74	0.40	0.25	0.38	0.38	0.38	0.38	0.38	0.38	0.38	3.76	610.98
Alendronate	227	Coronary artery disease	CP	204.39	0.76	0.26	0.35	0.48	0.48	0.48	0.48	0.48	0.48	0.48	3.75	767.32
Alendronate	187	rheumatic diseases	D	167.21	0.71	0.34	0.24	0.39	0.39	0.39	0.39	0.39	0.39	0.39	3.72	622.61
Alendronate	215	Renal dysfunction	CP	190.98	0.79	0.27	0.29	0.45	0.45	0.45	0.45	0.45	0.45	0.45	3.70	705.73
Alendronate	205	Hypercholesterolemia	CP	183.28	0.72	0.40	0.28	0.43	0.43	0.43	0.43	0.43	0.43	0.43	3.69	676.36
Alendronate	176	PRIMARY BILIARY CIRRHOSIS	D	158.67	0.75	0.21	0.30	0.37	0.37	0.37	0.37	0.37	0.37	0.37	3.68	584.56
Alendronate	149	Deminerlization	CP	135.12	0.75	0.43	0.30	0.32	0.32	0.32	0.32	0.32	0.32	0.32	3.65	493.52
Alendronate	209	Inflammatory bowel disease	CP	187.78	0.75	0.27	0.32	0.44	0.44	0.44	0.44	0.44	0.44	0.44	3.64	684.04
Alendronate	170	Prostatic carcinoma	CP	153.62	0.72	0.42	0.23	0.36	0.36	0.36	0.36	0.36	0.36	0.36	3.63	558.34
Alendronate	190	Peptic ulcer	CP	170.73	0.70	0.42	0.24	0.40	0.40	0.40	0.40	0.40	0.40	0.40	3.62	618.60
Alendronate	203	SARCOIDOSIS	D	183.27	0.78	0.23	0.32	0.43	0.43	0.43	0.43	0.43	0.43	0.43	3.61	662.19
Alendronate	184	PAI-1	D	164.96	0.61	0.23	0.24	0.38	0.38	0.38	0.38	0.38	0.38	0.38	3.61	595.61
Alendronate	202	GASTRIC CANCER	D	183.36	0.60	0.40	0.25	0.43	0.43	0.43	0.43	0.43	0.43	0.43	3.51	643.42
Alendronate	213	IDDM	D	191.46	0.74	0.24	0.32	0.45	0.45	0.45	0.45	0.45	0.45	0.45	3.51	671.25
Alendronate	167	THYROTOXICOSIS	D	149.57	0.75	0.26	0.24	0.35	0.35	0.35	0.35	0.35	0.35	0.35	3.50	523.55
Alendronate	170	BENIGN PROSTATIC	D	151.78	0.70	0.37	0.21	0.35	0.35	0.35	0.35	0.35	0.35	0.35	3.50	530.81
Alendronate	236	ANGIOTENSIN II	D	213.87	0.59	0.23	0.36	0.50	0.50	0.50	0.50	0.50	0.50	0.50	3.48	743.80
ATORVASTATIN	325	ATORVASTATIN	SM	274.04	0.97	0.97	0.97	0.71	0.71	0.71	0.71	0.71	0.71	0.71	8.87	2430.26
ATORVASTATIN	220	FISH OIL	SM	201.04	0.87	0.51	0.57	0.52	0.52	0.52	0.52	0.52	0.52	0.52	5.10	1026.12
ATORVASTATIN	224	Angina pectoris	CP	202.74	0.87	0.56	0.48	0.53	0.53	0.53	0.53	0.53	0.53	0.53	4.76	964.38
ATORVASTATIN	221	Hyperinsulinemia	CP	199.10	0.83	0.55	0.50	0.52	0.52	0.52	0.52	0.52	0.52	0.52	4.63	922.67
ATORVASTATIN	212	Arteriosclerosis	CP	192.14	0.85	0.50	0.45	0.50	0.50	0.50	0.50	0.50	0.50	0.50	4.50	863.81
ATORVASTATIN	197	diabetic nephropathy	G	177.77	0.80	0.42	0.34	0.46	0.46	0.46	0.46	0.46	0.46	0.46	4.42	786.21
ATORVASTATIN	230	Malondialdehyde	SM	207.49	0.84	0.46	0.51	0.54	0.54	0.54	0.54	0.54	0.54	0.54	4.36	904.86
ATORVASTATIN	217	essential hypertension	G	196.87	0.84	0.40	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	4.33	852.45
ATORVASTATIN	236	Prostacyclin	SM	213.79	0.82	0.37	0.40	0.56	0.56	0.56	0.56	0.56	0.56	0.56	4.32	923.69
ATORVASTATIN	233	alcohol consumption	O	210.13	0.73	0.40	0.53	0.55	0.55	0.55	0.55	0.55	0.55	0.55	4.32	906.97

Figure 25 Page 1 of 11

Query Object	Red	Implicit Relationship	Type	Quality	B Int S	C Int S	p Int	Imp V	Eq	Expect	Obs/Exp	Score
ATORVASTATIN	203	Lipid Peroxides	SM	185.40	0.78	0.47	0.50	0.48		43.14	4.30	796.77
ATORVASTATIN	176	chylomicrons	SM	159.27	0.84	0.67	0.52	0.41		37.14	4.29	683.07
ATORVASTATIN	179	Albuminuria	CP	161.60	0.81	0.41	0.31	0.42		37.68	4.29	693.03
ATORVASTATIN	225	end-stage renal disease	CP	201.76	0.82	0.36	0.35	0.52		47.05	4.29	865.17
ATORVASTATIN	191	Clofibrate	SM	174.16	0.86	0.47	0.50	0.45		40.69	4.28	745.44
ATORVASTATIN	185	DOCOSAHEXAENOIC ACID	SM	166.95	0.67	0.44	0.40	0.43		39.05	4.27	713.70
ATORVASTATIN	198	NITROGLYCERIN	SM	177.92	0.83	0.45	0.24	0.46		41.68	4.27	759.48
ATORVASTATIN	194	High blood pressure	CP	174.56	0.62	0.50	0.43	0.45		41.03	4.25	742.74
ATORVASTATIN	225	Linoleic Acid	SM	203.12	0.85	0.40	0.54	0.53		48.15	4.22	856.75
ATORVASTATIN	201	BETA-CAROTENE	SM	179.53	0.81	0.39	0.48	0.47		42.78	4.20	753.48
ATORVASTATIN	225	Nephrotic syndrome	CP	203.90	0.89	0.26	0.50	0.53		48.84	4.17	851.23
CELECOXIB	267	CELECOXIB	SM	228.96	0.95	0.95	0.95	0.69		27.63	8.29	1897.14
CELECOXIB	178	ANTI-INFLAMMATORY AGENT	SM	160.80	0.81	0.49	0.54	0.49		33.78	4.76	765.40
CELECOXIB	210	Salicylate	SM	189.23	0.83	0.36	0.64	0.57		42.43	4.46	843.84
CELECOXIB	199	leukotrienes	SM	181.54	0.88	0.38	0.54	0.55		41.32	4.39	797.72
CELECOXIB	187	Leukotriene B4	SM	170.75	0.80	0.36	0.52	0.52		39.06	4.37	746.36
CELECOXIB	186	Peptic ulcer	CP	170.61	0.81	0.38	0.55	0.52		39.17	4.36	743.06
CELECOXIB	177	Ranitidine	SM	160.76	0.75	0.25	0.42	0.49		37.12	4.33	696.31
CELECOXIB	166	Omeprazole	SM	151.11	0.78	0.23	0.40	0.46		35.05	4.31	651.39
CELECOXIB	210	Cimetidine	SM	193.34	0.80	0.25	0.54	0.59		45.06	4.29	829.67
CELECOXIB	167	PENTOXIFYLLINE	SM	151.37	0.64	0.32	0.36	0.46		35.47	4.27	646.01
CELECOXIB	185	PGE1	SM	167.68	0.78	0.34	0.43	0.51		39.69	4.23	708.48
CELECOXIB	201	Ulcerative colitis	CP	181.70	0.80	0.37	0.51	0.55		43.10	4.22	766.05
CELECOXIB	162	FISH OIL	SM	146.73	0.70	0.29	0.43	0.44		34.91	4.20	616.71
CELECOXIB	187	prostaglandin E1	CP	169.84	0.78	0.27	0.43	0.51		40.91	4.15	705.18
CELECOXIB	182	Lipoxygenase	SM	166.41	0.85	0.41	0.48	0.50		40.44	4.12	684.81
CELECOXIB	156	PGD2	SM	142.12	0.80	0.47	0.37	0.43		34.68	4.10	582.51
CELECOXIB	189	Oral Contraceptives	SM	169.91	0.68	0.23	0.40	0.51		41.48	4.10	695.99
CELECOXIB	192	C-reactive protein	G	175.35	0.77	0.26	0.51	0.53		42.93	4.08	716.14
CELECOXIB	189	ET-1	SM	172.90	0.78	0.33	0.40	0.52		42.48	4.07	703.76
CELECOXIB	177	Endothelin	SM	161.40	0.76	0.34	0.35	0.49		39.70	4.07	656.13
CELECOXIB	170	BETA-CAROTENE	SM	152.73	0.61	0.30	0.30	0.46		37.67	4.06	619.34
Finasteride	233	Infertility	CP	211.55	0.80	0.34	0.45	0.47		52.67	4.02	849.68
Finasteride	165	Hyperprolactinemia	CP	150.42	0.68	0.43	0.32	0.33		38.36	3.92	589.88
Finasteride	241	BODY MASS INDEX	D	219.31	0.83	0.32	0.48	0.48		57.32	3.83	839.15

Figure 25 Page 2 of 11

Query Object	Ref	Implicit Relationship	Type	Quality	B In S	C In S	p In S	Temp V	Acc	Expt	Ops Exp	Score
Finasteride	168	ENDOMETRIOSIS	D	153.10	0.59	0.40	0.28	0.34		40.67	3.76	576.32
Finasteride	157	Endometrial carcinoma	CP	141.59	0.54	0.52	0.24	0.31		38.63	3.67	519.03
Finasteride	202	Ovarian cancer	CP	182.81	0.72	0.35	0.32	0.40		50.48	3.62	662.05
Finasteride	169	CORTICOTROPIN-RELEASING	D	152.08	0.48	0.34	0.23	0.34		42.04	3.62	550.14
Finasteride	161	Amenorrhea	CP	147.44	0.53	0.39	0.32	0.33		40.89	3.61	531.59
Finasteride	216	Breast carcinoma	CP	194.31	0.72	0.46	0.34	0.43		54.29	3.58	695.52
Finasteride	234	prostaglandin E2	CP	211.91	0.70	0.20	0.31	0.47		59.26	3.58	757.78
Finasteride	138	Precocious puberty	CP	125.93	0.67	0.45	0.26	0.28		35.38	3.56	448.17
Finasteride	197	Insulin resistance	CP	178.64	0.64	0.20	0.41	0.39		50.30	3.55	634.39
Finasteride	210	Osteoporosis	CP	191.24	0.73	0.33	0.40	0.42		54.29	3.52	673.63
Finasteride	195	Bone Resorption	D	177.56	0.75	0.30	0.33	0.39		50.49	3.52	624.40
Finasteride	176	Pancreatic cancer	CP	157.63	0.67	0.35	0.25	0.35		45.11	3.49	550.72
Finasteride	165	CERVICAL CANCER	D	148.42	0.54	0.46	0.23	0.33		42.86	3.46	514.01
Finasteride	230	ANGIOTENSIN II	D	209.19	0.71	0.21	0.35	0.46		61.04	3.43	716.96
Finasteride	154	HMG-CoA REDUCTASE	D	136.56	0.47	0.31	0.18	0.30		40.33	3.39	462.43
Finasteride	166	PAL-1	D	150.43	0.65	0.19	0.23	0.33		44.65	3.37	506.76
Finasteride	160	Choriocarcinoma	D	142.53	0.46	0.33	0.21	0.31		42.47	3.36	478.30
Finasteride	210	Type 2 diabetes	D	191.15	0.75	0.17	0.34	0.42		57.29	3.34	637.81
Finasteride	261	LIPOPROTEIN	D	237.54	0.84	0.35	0.50	0.52		71.52	3.32	788.96
Finasteride	118	Anovulation	D	107.60	0.46	0.51	0.23	0.24		32.69	3.29	354.20
Finasteride	177	BETA-ADRENERGIC RECEPTOR	D	159.55	0.47	0.20	0.23	0.35		48.71	3.28	522.63
Finasteride	244	Cysts	D	222.04	0.77	0.30	0.39	0.49		68.75	3.23	717.11
Fluoxetine	597	Cerebral ischemia	CP	539.08	0.55	0.59	0.20	0.36		148.40	3.63	1958.35
Fluoxetine	508	Ventricular fibrillation	CP	460.59	0.54	0.60	0.14	0.31		133.48	3.45	1589.29
Fluoxetine	487	Ventricular tachycardia	CP	440.43	0.52	0.60	0.14	0.29		129.29	3.41	1500.31
Fluoxetine	479	Hyperventilation	CP	434.21	0.50	0.57	0.16	0.29		127.80	3.40	1475.25
Fluoxetine	548	Myocardial Ischemia	D	497.89	0.54	0.55	0.21	0.33		147.12	3.38	1684.96
Fluoxetine	616	Coronary artery disease	CP	561.26	0.55	0.54	0.26	0.37		167.18	3.36	1884.29
Fluoxetine	550	prostaglandin E1	CP	499.03	0.53	0.53	0.15	0.33		148.67	3.36	1675.11
Fluoxetine	626	Acidosis	CP	566.73	0.50	0.49	0.19	0.38		169.56	3.34	1894.27
Fluoxetine	525	Angina	CP	475.28	0.53	0.57	0.22	0.32		142.74	3.33	1582.57
Fluoxetine	691	Ulcer	CP	627.52	0.62	0.44	0.22	0.42		190.67	3.29	2065.30
Fluoxetine	537	Ischemic heart disease	CP	487.22	0.52	0.54	0.16	0.32		148.89	3.27	1594.40
Fluoxetine	695	Encephalopathy	CP	630.45	0.65	0.43	0.24	0.42		193.46	3.26	2054.50
Fluoxetine	455	High blood pressure	CP	408.49	0.45	0.64	0.13	0.27		126.01	3.24	1324.19

Figure 25 Page 3 of 11





Query Object	Test	Implicit Relationship	Type	Quality	B Int	S Int	S p Int	Imp	Y	Exp	Ops	Exp	Score
INDINAVIR	293	Chronic hepatitis	CP	263.60	0.59	0.48	0.33	0.42		68.26	3.86		1017.93
INDINAVIR	284	beta 2-Microglobulin	SM	254.96	0.59	0.37	0.24	0.41		66.14	3.86		982.93
INDINAVIR	273	Liver failure	CP	244.25	0.66	0.35	0.18	0.39		63.41	3.85		940.82
INDINAVIR	268	Normal renal function	CP	238.73	0.45	0.41	0.16	0.38		62.08	3.85		918.07
INDINAVIR	260	Skin rash	CP	230.63	0.64	0.40	0.14	0.37		60.26	3.83		882.60
INDINAVIR	287	end-stage renal disease	CP	256.49	0.52	0.38	0.20	0.41		67.39	3.81		976.23
INDINAVIR	296	Azathioprine	SM	265.53	0.43	0.44	0.19	0.42		70.13	3.79		1005.43
INDINAVIR	275	Liver dysfunction	CP	245.30	0.62	0.37	0.17	0.39		64.81	3.79		928.51
INDINAVIR	312	METHYLPREDNISOLONE	SM	280.70	0.53	0.35	0.20	0.45		74.48	3.77		1057.93
INDINAVIR	268	Arthralgia	CP	238.74	0.44	0.35	0.16	0.38		63.48	3.76		897.77
INDINAVIR	292	Nephrotic syndrome	CP	261.22	0.60	0.43	0.20	0.42		70.14	3.72		972.90
INDINAVIR	309	Cimetidine	SM	277.94	0.70	0.23	0.19	0.44		74.77	3.72		1033.17
INDINAVIR	264	Myalgia	CP	235.75	0.43	0.39	0.16	0.38		63.73	3.70		872.02
INDINAVIR	274	Chronic Infection	CP	248.04	0.59	0.40	0.23	0.40		67.21	3.69		915.44
INDINAVIR	297	Lymphadenopathy	CP	266.07	0.53	0.41	0.25	0.43		72.25	3.68		979.78
INDINAVIR	257	Allopurinol	SM	229.32	0.46	0.29	0.16	0.37		62.49	3.67		841.55
INDINAVIR	275	AMPHOTERICIN B	SM	247.33	0.63	0.43	0.22	0.40		67.66	3.66		904.07
INDINAVIR	277	IBUPROFEN	SM	244.89	0.46	0.26	0.16	0.39		67.02	3.65		894.80
LOSARTAN	541	Angina pectoris	CP	498.49	0.82	0.77	0.36	0.39		121.88	4.09		2038.81
LOSARTAN	621	brain injury	D	571.79	0.76	0.58	0.30	0.45		141.78	4.03		2305.93
LOSARTAN	487	Endotoxemia	D	447.01	0.70	0.65	0.23	0.35		114.85	3.89		1739.79
LOSARTAN	565	Septic Shock	D	519.19	0.74	0.54	0.28	0.41		134.39	3.86		2005.76
LOSARTAN	512	Subarachnoid hemorrhage	CP	471.43	0.72	0.48	0.29	0.37		122.30	3.85		1817.16
LOSARTAN	661	Hypothermia	CP	607.05	0.81	0.59	0.35	0.48		159.08	3.82		2316.53
LOSARTAN	501	Arteriosclerosis	CP	458.84	0.80	0.65	0.25	0.36		122.26	3.75		1721.97
LOSARTAN	574	RESPIRATORY DISTRESS	D	528.87	0.79	0.43	0.28	0.41		140.94	3.75		1984.56
LOSARTAN	618	Liver cirrhosis	CP	564.29	0.83	0.44	0.30	0.44		151.14	3.73		2106.72
LOSARTAN	454	Hyperoxia	CP	413.82	0.69	0.68	0.19	0.32		111.88	3.70		1530.63
LOSARTAN	691	Alzheimer's disease	D	638.53	0.76	0.43	0.33	0.50		173.54	3.68		2349.44
LOSARTAN	432	Hemorrhagic Shock	CP	394.97	0.72	0.69	0.19	0.31		108.08	3.65		1443.34
LOSARTAN	502	Chronic obstructive pulmonary	CP	459.37	0.79	0.50	0.27	0.36		125.90	3.65		1676.13
LOSARTAN	545	Cardiac arrhythmias	D	501.22	0.81	0.61	0.32	0.39		138.97	3.61		1807.73
LOSARTAN	544	Bone Resorption	D	500.16	0.63	0.50	0.22	0.39		141.06	3.55		1773.42
LOSARTAN	510	Spasm	D	467.36	0.73	0.60	0.27	0.37		134.09	3.49		1628.93
LOSARTAN	714	Rupture	D	659.14	0.84	0.47	0.39	0.52		191.88	3.44		2264.31

Figure 25 Page 5 of 11

Object	Ref	Implicit Relationship	Type	Quality	B	In	S	C	In	S	Ph	App	V	Sc	En	Exp	Score
LOSARTAN	577	Parkinson's Disease	D	527.10	0.70	0.37	0.25	0.41							153.98	3.42	1804.39
LOSARTAN	740	Sepsis	D	685.18	0.83	0.41	0.43	0.54							202.06	3.39	2323.45
LOSARTAN	553	PROSTATE CANCER	D	508.70	0.61	0.44	0.22	0.40							153.11	3.32	1690.07
LOSARTAN	471	Cerebral Infarction	D	428.73	0.74	0.53	0.23	0.34							129.11	3.32	1423.64
LOSARTAN	548	Aneurysm	D	506.25	0.79	0.51	0.33	0.40							152.51	3.32	1680.49
LOSARTAN	439	Cholera	D	398.12	0.59	0.46	0.16	0.31							120.60	3.30	1314.33
LOSARTAN	529	Osteoarthritis	D	482.62	0.63	0.45	0.24	0.38							146.99	3.28	1584.68
OLANZAPINE	477	OLANZAPINE	SM	409.37	0.98	0.98	0.98	0.77							37.56	10.90	4461.43
OLANZAPINE	245	Anxiety disorder	D	222.74	0.56	0.70	0.31	0.42							42.09	5.29	1178.64
OLANZAPINE	261	monoamine oxidase inhibitors	SM	237.11	0.71	0.53	0.27	0.45							45.66	5.19	1231.36
OLANZAPINE	282	Homovanillic Acid	SM	257.57	0.84	0.62	0.40	0.48							49.92	5.16	1329.00
OLANZAPINE	237	METHYLPHENIDATE	SM	213.41	0.79	0.59	0.24	0.40							41.42	5.15	1099.41
OLANZAPINE	219	PANIC DISORDER	D	200.44	0.54	0.57	0.26	0.38							40.79	4.91	984.94
OLANZAPINE	244	Disinhibition	CP	220.04	0.80	0.57	0.23	0.41							44.87	4.90	1079.19
OLANZAPINE	251	Sleep disturbance	CP	228.77	0.80	0.51	0.24	0.43							46.81	4.89	1118.00
OLANZAPINE	232	autoreceptors	SM	211.33	0.78	0.67	0.28	0.40							43.42	4.87	1028.44
OLANZAPINE	244	METHAMPHETAMINE	SM	219.86	0.78	0.60	0.29	0.41							45.82	4.80	1055.02
OLANZAPINE	296	Migraine	CP	267.59	0.72	0.41	0.30	0.50							57.34	4.67	1248.70
OLANZAPINE	327	Naloxone	SM	298.67	0.86	0.41	0.39	0.56							64.37	4.64	1385.82
OLANZAPINE	268	YOHIMBINE	SM	243.58	0.77	0.48	0.30	0.46							52.65	4.63	1126.77
OLANZAPINE	266	Myoclonus	CP	238.79	0.67	0.39	0.24	0.45							51.64	4.62	1104.16
OLANZAPINE	238	Cyproheptadine	SM	216.79	0.66	0.48	0.24	0.41							47.13	4.60	997.28
OLANZAPINE	300	Monoamine oxidase	G	275.56	0.85	0.39	0.35	0.52							60.43	4.56	1256.50
OLANZAPINE	244	Physostigmine	SM	222.28	0.65	0.49	0.26	0.42							48.77	4.56	1012.96
OLANZAPINE	217	LITHIUM CARBONATE	SM	194.15	0.65	0.55	0.20	0.37							43.00	4.52	876.72
OLANZAPINE	239	Amnesia	D	214.85	0.53	0.40	0.21	0.40							47.78	4.50	966.10
OLANZAPINE	326	gamma-Aminobutyric Acid	SM	298.24	0.85	0.52	0.36	0.56							66.70	4.47	1333.41
OLANZAPINE	256	Midazolam	SM	232.03	0.55	0.36	0.22	0.44							51.95	4.47	1036.42
OLANZAPINE	290	Melatonin	SM	264.10	0.83	0.37	0.31	0.50							59.73	4.42	1167.83
Omeprazole	1419	Omeprazole	SM	1235.92	0.98	0.98	0.98	0.77							262.60	4.71	5816.86
Omeprazole	834	Tachykinin	D	763.93	0.66	2.65	0.27	0.48							229.93	3.32	2538.10
Omeprazole	843	calcium channel	O	768.36	0.73	1.47	0.23	0.48							232.27	3.31	2541.80
Omeprazole	807	bradykinin	G	737.98	0.54	2.03	0.24	0.46							223.27	3.31	2439.25
Omeprazole	921	noradrenaline	SM	844.80	0.66	4.17	0.31	0.53							262.04	3.22	2723.61
Omeprazole	852	Hyperglycemia	CP	778.04	0.67	1.62	0.23	0.49							244.26	3.19	2478.31

Figure 25 Page 6 of 11



Query Object	Id	Implicit Relationship	Type	Quality	B	Int	C	Int	S	p	Int	Imp	Y	Act	Expect	Obs	Exp	Score
PIOGLITAZONE	152	COLORECTAL CANCER	D	135.81	0.64	0.27	0.34	0.41							38.74	3.51		476.10
PIOGLITAZONE	159	PROSTATE CANCER	D	143.09	0.79	0.28	0.34	0.43							40.96	3.49		499.88
PIOGLITAZONE	174	Alzheimer's disease	D	157.53	0.83	0.13	0.45	0.47							45.72	3.45		542.70
ROFECOXIB	156	Peptic ulcer	CP	142.19	0.81	0.40	0.53	0.61							32.39	4.39		624.24
ROFECOXIB	157	prostaglandin E1	CP	143.56	0.79	0.25	0.47	0.61							33.78	4.25		610.08
ROFECOXIB	150	Anaphylaxis	D	134.78	0.77	0.30	0.42	0.58							31.77	4.24		571.78
ROFECOXIB	150	Gastritis	CP	136.48	0.80	0.33	0.46	0.58							32.86	4.15		566.89
ROFECOXIB	154	Spasm	D	138.55	0.74	0.33	0.41	0.59							33.54	4.13		572.37
ROFECOXIB	144	Chronic obstructive pulmonary	CP	130.58	0.62	0.28	0.38	0.56							31.88	4.10		534.83
ROFECOXIB	138	rheumatic diseases	D	125.49	0.79	0.31	0.55	0.54							31.04	4.04		507.37
ROFECOXIB	156	Inflammatory bowel disease	CP	141.33	0.84	0.24	0.46	0.60							35.09	4.03		569.27
ROFECOXIB	156	Colitis	D	141.29	0.85	0.25	0.45	0.60							35.26	4.01		566.13
ROFECOXIB	147	Myocardial Ischemia	D	133.62	0.66	0.37	0.40	0.57							33.53	3.99		532.49
ROFECOXIB	161	Chronic Inflammation	CP	145.94	0.86	0.30	0.49	0.62							36.65	3.98		581.10
ROFECOXIB	148	Cerebral ischemia	CP	133.74	0.72	0.37	0.39	0.57							33.74	3.96		530.10
ROFECOXIB	142	Migraine	CP	129.08	0.64	0.39	0.52	0.55							32.74	3.94		508.95
ROFECOXIB	155	Ulcerative colitis	CP	140.09	0.78	0.23	0.44	0.60							35.55	3.94		552.06
ROFECOXIB	132	Reperfusion Injury	D	119.68	0.62	0.40	0.35	0.51							30.38	3.94		471.48
ROFECOXIB	135	Angina pectoris	CP	122.29	0.55	0.34	0.33	0.52							31.07	3.94		481.30
ROFECOXIB	146	Pulmonary Edema	D	132.96	0.62	0.27	0.38	0.57							33.99	3.91		520.07
ROFECOXIB	141	Angina	CP	127.73	0.53	0.40	0.36	0.55							32.80	3.89		497.38
ROFECOXIB	169	Renal insufficiency	CP	153.52	0.85	0.23	0.52	0.66							39.48	3.89		596.89
ROFECOXIB	148	Pulmonary hypertension	CP	134.87	0.77	0.26	0.42	0.58							34.84	3.87		522.02
ROFECOXIB	118	Pleurisy	CP	104.80	0.68	0.27	0.35	0.45							27.16	3.86		404.44
ROFECOXIB	142	Bronchial asthma	CP	127.93	0.55	0.28	0.41	0.55							33.30	3.84		491.51
ROFECOXIB	154	Peritonitis	CP	140.31	0.78	0.21	0.45	0.60							36.60	3.83		537.88
ROFECOXIB	158	Liver cirrhosis	CP	141.79	0.77	0.18	0.38	0.61							36.99	3.83		543.52
ROFECOXIB	127	High blood pressure	CP	115.04	0.56	0.35	0.28	0.49							30.03	3.83		440.80
ROFECOXIB	124	peripheral vascular disease	CP	111.89	0.52	0.35	0.29	0.48							29.21	3.83		428.63
ROFECOXIB	148	RESPIRATORY DISTRESS	D	133.74	0.70	0.20	0.42	0.57							34.93	3.83		512.13
ROFECOXIB	173	ANGIOTENSIN II	D	157.25	0.88	0.26	0.45	0.67							41.16	3.82		600.80
ROFECOXIB	125	Endotoxemia	D	112.66	0.66	0.31	0.37	0.48							29.65	3.80		428.10
ROFECOXIB	142	BETA-ADRENERGIC RECEPTOR	D	128.35	0.65	0.12	0.33	0.55							33.90	3.79		485.94
ROFECOXIB	148	GLUTATHIONE PEROXIDASE	D	133.94	0.76	0.18	0.40	0.57							35.65	3.76		503.21
ROFECOXIB	131	PAI-1	D	118.11	0.67	0.18	0.33	0.50							31.51	3.75		442.71

Figure 25 Page 8 of 11

Query/Subject	Index	Implicit Relationship	Type	Quality	Blind S	C-Int S	Sp Int	Imp V	Effect	Expect	Obs/Exp	Score
Sertraline	300	Delirium	D	272.18	0.80	0.62	0.31	0.40		56.65	4.80	1307.66
Sertraline	352	amygdala	CP	320.50	0.84	0.66	0.36	0.47		71.27	4.50	1441.32
Sertraline	244	Sleep Deprivation	D	220.15	0.76	0.60	0.25	0.32		50.53	4.36	959.09
Sertraline	249	sleep disorders	CP	224.29	0.65	0.51	0.22	0.33		52.07	4.31	966.25
Sertraline	394	Exploratory	CP	356.79	0.83	0.41	0.35	0.52		86.81	4.11	1466.39
Sertraline	254	Hyperalgesia	D	227.89	0.55	0.41	0.17	0.33		56.17	4.06	924.52
Sertraline	225	Catalepsy	D	205.30	0.66	0.62	0.18	0.30		51.05	4.02	825.69
Sertraline	239	Tiredness	CP	215.13	0.64	0.54	0.17	0.31		54.48	3.95	849.44
Sertraline	231	Cognitive dysfunction	CP	205.59	0.45	0.57	0.18	0.30		52.47	3.92	805.56
Sertraline	421	Epilepsy	CP	383.32	0.82	0.50	0.42	0.56		100.21	3.83	1466.23
Sertraline	362	Vasoconstriction	CP	325.10	0.61	0.38	0.31	0.47		85.28	3.81	1239.41
Sertraline	251	Disorientation	CP	223.66	0.56	0.43	0.16	0.33		60.01	3.73	833.60
Sertraline	243	Asthenia	CP	217.24	0.73	0.47	0.16	0.32		58.54	3.71	806.11
Sertraline	286	Angina	CP	257.03	0.48	0.47	0.27	0.38		69.49	3.70	950.76
Sertraline	256	Hyperventilation	CP	231.77	0.47	0.35	0.21	0.34		62.66	3.70	857.29
Sertraline	250	Palpitations	CP	223.05	0.56	0.53	0.19	0.33		60.31	3.70	824.89
Sertraline	294	Spasm	D	264.25	0.52	0.41	0.23	0.39		71.52	3.69	976.28
Sertraline	276	Myocardial Ischemia	D	246.93	0.47	0.42	0.26	0.36		71.49	3.45	852.88
Sertraline	351	ANGIOTENSIN II	D	317.20	0.57	0.33	0.29	0.46		92.50	3.43	1087.69
Sertraline	169	NARCOLEPSY	D	152.19	0.57	0.43	0.13	0.22		46.00	3.31	503.48
Sertraline	196	Senile dementia	D	174.49	0.43	0.52	0.14	0.25		52.83	3.30	576.36
Sertraline	175	chronic fatigue syndrome	D	157.43	0.55	0.55	0.16	0.23		48.33	3.26	512.84
Simvastatin	413	High blood pressure	CP	373.10	0.65	0.70	0.29	0.41		91.17	4.09	1526.79
Simvastatin	526	Liver cirrhosis	CP	474.48	0.69	0.51	0.27	0.52		117.49	4.04	1916.10
Simvastatin	391	Preeclampsia	CP	356.90	0.60	0.50	0.21	0.39		89.73	3.98	1419.53
Simvastatin	390	Fatty liver	CP	352.77	0.76	0.57	0.26	0.39		90.35	3.90	1377.49
Simvastatin	390	Glucose intolerance	CP	350.73	0.70	0.69	0.29	0.38		90.24	3.89	1363.20
Simvastatin	444	Chronic liver disease	CP	397.42	0.60	0.48	0.21	0.43		103.69	3.83	1523.20
Simvastatin	469	GLUTATHIONE PEROXIDASE	D	424.75	0.74	0.59	0.31	0.46		112.43	3.78	1604.73
Simvastatin	413	Hepatic dysfunction	CP	369.47	0.76	0.46	0.17	0.40		98.47	3.75	1386.30
Simvastatin	406	Chronic obstructive pulmonary	CP	365.03	0.60	0.39	0.20	0.40		98.19	3.72	1357.03
Simvastatin	446	Cholestasis	CP	404.84	0.75	0.52	0.26	0.44		109.02	3.71	1503.40
Simvastatin	367	Endotoxemia	D	330.98	0.53	0.52	0.18	0.36		89.75	3.69	1220.65
Simvastatin	426	Septic Shock	D	384.86	0.55	0.46	0.21	0.42		104.69	3.68	1414.84
Simvastatin	522	prostaglandin E2	CP	474.54	0.68	0.48	0.26	0.52		129.30	3.67	1741.59

Figure 25 Page 9 of 11

Query Object	Id	Implicit Relationship	Type	Quality	B	In	S	C	n	S	p	Int	Imp	V	Exp	Obs	Exp	Score
Simvastatin	497	Cardiomyopathy	CP	451.41		0.78		0.50		0.29		0.49			123.65		3.65	1647.95
Simvastatin	361	Diabetic Retinopathy	D	326.28		0.58		0.51		0.19		0.36			89.45		3.65	1190.09
Simvastatin	442	RESPIRATORY DISTRESS	D	397.49		0.59		0.35		0.21		0.43			109.69		3.62	1440.40
Simvastatin	420	BETA-ADRENERGIC RECEPTOR	D	377.98		0.58		0.42		0.20		0.41			105.82		3.57	1350.07
Simvastatin	330	Pre-Eclampsia	D	297.51		0.53		0.49		0.15		0.32			83.82		3.55	1055.97
Simvastatin	387	DILATED CARDIOMYOPATHY	D	349.61		0.58		0.55		0.20		0.38			99.39		3.52	1229.80
Simvastatin	276	Hyperhomocysteinemia	D	251.55		0.61		0.63		0.17		0.27			72.26		3.48	875.72
Simvastatin	503	CYSTIC FIBROSIS	D	456.17		0.70		0.35		0.25		0.50			131.33		3.47	1584.49
Simvastatin	455	PROSTATE CANCER	D	412.68		0.65		0.48		0.20		0.45			119.00		3.47	1431.16
Simvastatin	404	Pulmonary Edema	D	366.69		0.49		0.45		0.20		0.40			106.16		3.45	1266.56
Simvastatin	412	Cardiac arrhythmias	D	373.31		0.60		0.40		0.20		0.41			108.19		3.45	1288.12
Simvastatin	427	GASTRIC CANCER	D	382.82		0.57		0.41		0.19		0.42			111.94		3.42	1309.25
Simvastatin	390	Hepatitis C	D	351.74		0.58		0.46		0.18		0.38			103.37		3.40	1196.89
Simvastatin	508	Systemic lupus erythematosus	D	463.51		0.69		0.35		0.28		0.51			136.26		3.40	1576.73
Simvastatin	416	Colitis	D	374.01		0.45		0.31		0.18		0.41			110.97		3.37	1260.60
Simvastatin	436	Aneurysm	D	397.65		0.66		0.52		0.24		0.43			118.54		3.35	1333.94
Simvastatin	421	Osteoarthritis	D	380.97		0.59		0.35		0.19		0.42			114.32		3.33	1269.60
TIROFIBAN	136	TIROFIBAN	SM	114.41		0.97		0.97		0.97		0.78			11.57		9.89	1131.04
TIROFIBAN	91	Fibrinopeptide A	SM	83.30		0.89		0.43		0.51		0.57			14.02		5.94	494.82
TIROFIBAN	101	STREPTOKINASE	SM	91.50		0.91		0.54		0.59		0.63			15.59		5.87	536.93
TIROFIBAN	97	Antithrombin	CP	88.08		0.91		0.37		0.53		0.60			15.06		5.85	515.21
TIROFIBAN	87	VENOUS THROMBOEMBOLISM	D	78.26		0.76		0.39		0.50		0.54			14.30		5.47	428.22
TIROFIBAN	97	peripheral vascular disease	CP	87.58		0.79		0.28		0.48		0.60			16.13		5.43	475.53
TIROFIBAN	94	Coronary Disease	D	84.28		0.78		0.47		0.43		0.58			15.60		5.40	455.39
TIROFIBAN	90	Coronary atherosclerosis	CP	80.89		0.61		0.35		0.39		0.55			15.00		5.39	436.34
TIROFIBAN	95	Arterial occlusion	CP	85.30		0.78		0.36		0.44		0.58			15.86		5.38	458.80
TIROFIBAN	92	Deep vein thrombosis	CP	82.74		0.65		0.39		0.53		0.57			15.49		5.34	441.98
TIROFIBAN	102	Angina pectoris	CP	92.03		0.66		0.47		0.50		0.63			17.33		5.31	488.85
TIROFIBAN	101	Atrial fibrillation	CP	92.25		0.67		0.28		0.55		0.63			17.39		5.30	489.34
TIROFIBAN	111	WARFARIN	SM	100.43		0.84		0.43		0.62		0.69			18.99		5.29	531.27
TIROFIBAN	76	Peripheral arterial disease	CP	67.39		0.72		0.34		0.36		0.46			13.03		5.17	348.48
TIROFIBAN	83	Cardiogenic Shock	D	75.81		0.88		0.48		0.46		0.52			14.78		5.13	388.81
TIROFIBAN	91	PLASMINOGEN ACTIVATOR	Gh	82.06		0.64		0.21		0.44		0.56			16.06		5.11	419.35
TIROFIBAN	85	Transient ischemic attacks	CP	77.08		0.85		0.49		0.49		0.53			15.14		5.09	392.51
TIROFIBAN	77	Coronary Stenosis	D	68.61		0.71		0.57		0.35		0.47			13.49		5.09	349.06

Figure 25 Page 10 of 11

Query object	req	Implicit Relationship	Type	Quality	B	n	S	C	n	S	p	Int	Imp	V	ect	Ex	act	Cost	Exp	Score
TIROFIBAN	80	Intermittent claudication	CP	71.37	0.54	0.27	0.33	0.49	14.10	5.06	361.21									
TIROFIBAN	86	ABDOMINAL AORTIC	D	76.79	0.61	0.30	0.38	0.53	15.20	5.05	387.95									
TIROFIBAN	105	UROKINASE	G	94.50	0.82	0.25	0.60	0.65	18.71	5.05	477.32									
TIROFIBAN	95	Reperfusion Injury	D	85.27	0.77	0.31	0.40	0.58	16.88	5.05	430.66									

Figure 25 Page 11 of 11






FIG. 26



Objectname	#	Quality	Expect	Obs/Exp	2 sigma	Notes
Cytokine	15	8.80	8.49	1.04	-0.40	Inflammation & immune res
Kinase	15	7.66	8.97	0.85	-0.59	Kinases are frequently invol
Carcinoma	15	8.33	10.01	0.83	-0.61	Broad association for a num
Actin	14	11.61	6.42	1.81	0.37	Cell growth & metastasis
Transcription Factors	14	11.60	6.79	1.71	0.27	Induction of new metabolic p
repetitive sequence	14	10.67	6.91	1.54	0.10	Polymorphisms?
BREAST CANCER	14	8.90	6.45	1.38	-0.06	<-- Tissue type studied in thi
Adenocarcinoma	14	9.38	6.86	1.37	-0.07	These genes are also involv
Serine	14	11.53	8.96	1.29	-0.15	Serine proteases can dissoh
EGF	14	6.81	5.90	1.15	-0.29	Epidermal growth factor
Apoptosis	14	6.49	8.58	0.76	-0.68	Shutting down apoptosis aid
Calcium	14	7.45	10.16	0.73	-0.71	
Ribosomal RNA	13	10.65	4.44	2.40	0.96	
Ribonuclease	13	11.80	6.22	1.90	0.46	
Alternative splicing	13	10.59	5.88	1.80	0.36	Some of these genes may b
Chromatin	13	10.05	5.83	1.72	0.28	Remodeling for transcription
Fibronectin	13	9.23	5.36	1.72	0.28	Connective tissue
Threonine	13	10.81	6.93	1.56	0.12	
Tyrosine kinase	13	7.12	5.48	1.30	-0.14	
Alkaline Phosphatase	13	9.03	7.00	1.29	-0.15	
Phosphatase	13	8.17	6.85	1.19	-0.25	
Immunoglobulin G	13	8.98	8.18	1.10	-0.34	
Glycoprotein	13	7.98	8.27	0.97	-0.47	
Glucose	13	8.40	9.65	0.87	-0.57	
Sodium	13	8.53	10.88	0.78	-0.66	
Myosin	12	10.39	4.58	2.27	0.83	
Methionine	12	10.72	5.92	1.81	0.37	
HEREDITARY NONPOLYPOSIS COLORECTAL CANCER	12	6.48	3.79	1.71	0.27	
Tumorigenesis	12	7.06	4.24	1.67	0.23	
Cysteine	12	9.48	7.72	1.23	-0.21	
Melanoma	12	6.15	5.99	1.03	-0.41	
INS	12	8.16	8.10	1.01	-0.43	
secreted	12	7.37	7.54	0.98	-0.46	
Immunoglobulin	12	7.81	8.17	0.96	-0.48	
Dexamethasone	12	6.40	6.71	0.95	-0.49	
Translocation	12	7.71	8.37	0.92	-0.52	
Estrogen Receptors	11	8.98	2.68	3.35	1.91	
ERBB2	11	6.64	2.12	3.13	1.69	
Antisense Oligonucleotides	11	9.78	3.20	3.06	1.62	
Untranslated Regions	11	7.91	2.62	3.01	1.57	
Surface Antigens	11	9.44	3.61	2.62	1.18	
Keratin	11	9.47	3.64	2.60	1.16	
NP220	11	10.33	4.06	2.54	1.10	
MULTIPLE MYELOMA	11	6.78	3.75	1.81	0.37	
TYPE 1B CHARCOT-MARIE-TOOTH DISEASE	11	9.48	5.29	1.79	0.35	
Interleukin-2	11	8.09	4.74	1.71	0.27	
Laminin	11	6.93	4.24	1.63	0.19	
Phorbol	11	9.30	5.71	1.63	0.19	
Lectin	11	8.09	5.12	1.58	0.14	
PROSTATE CANCER	11	6.47	4.13	1.57	0.13	
EGFR	11	5.06	3.30	1.53	0.09	

FIG. 27-1

Cycloheximide	11	9.05	5.91	1.53	0.09
IL2	11	8.13	5.59	1.45	0.01
ESR1	11	7.90	5.52	1.43	-0.01
Progesterone	11	7.98	5.70	1.40	-0.04
Immunoglobulin M	11	8.56	6.18	1.38	-0.06
Collagenase	11	6.40	4.71	1.36	-0.08
Melastasis	11	7.74	5.92	1.31	-0.13
Sarcoma	11	7.30	5.62	1.30	-0.14
Integrin	11	5.74	4.62	1.24	-0.20
LUNG CANCER	11	6.62	5.34	1.24	-0.20
Trypsin	11	7.50	6.53	1.15	-0.29
Ischemia	11	7.12	6.28	1.13	-0.31
Hypertrophy	11	7.63	7.15	1.07	-0.37
Adenoma	11	5.58	5.29	1.05	-0.39
Estrogen	11	5.88	5.89	1.00	-0.44
Chloride	11	7.74	7.76	1.00	-0.44
Membrane Proteins	11	7.54	7.84	0.96	-0.48
Hyperplasia	11	6.55	6.90	0.95	-0.49
Lymphoma	11	6.50	6.96	0.93	-0.51
Adenosine Triphosphate	11	7.32	8.27	0.89	-0.55
Acetate	11	6.99	8.14	0.86	-0.58
ras Proteins	11	3.81	5.06	0.75	-0.69
Collagen	11	6.16	8.18	0.75	-0.69
Oxygen	11	6.74	9.14	0.74	-0.70
Necrosis	11	6.64	9.10	0.73	-0.71
Fatty Acids	11	4.74	7.59	0.62	-0.82
KALLIKREIN 3	10	7.29	2.55	2.86	1.16
Steroid Receptors	10	7.56	2.82	2.68	0.98
PGR	10	6.99	2.75	2.54	0.84
Nuclear Proteins	10	9.60	3.78	2.54	0.84
Caspase	10	8.42	3.38	2.49	0.79
DNA Probes	10	8.63	3.71	2.32	0.62
Staurosporine	10	8.72	3.82	2.29	0.59
CEACAM5	10	7.37	3.23	2.28	0.58
COLONY-STIMULATING FACTOR 3	10	7.60	3.46	2.19	0.49
Tissue Extracts	10	7.90	3.61	2.19	0.49
Oligonucleotide Probes	10	8.11	3.72	2.18	0.48
NR4A1	10	7.40	3.44	2.15	0.45
DNA-Binding Proteins	10	8.21	3.84	2.14	0.44
MPO	10	8.26	4.02	2.06	0.36
KRT1	10	6.95	3.46	2.01	0.31
SNTA1	10	9.48	4.77	1.99	0.29
VIM	10	8.06	4.08	1.98	0.28
Glioblastoma	10	6.54	3.32	1.97	0.27
Histone	10	8.23	4.19	1.96	0.26
Deoxyribonuclease	10	9.08	4.64	1.96	0.26
Starvation	10	8.56	4.78	1.79	0.09
GAMMA CCAAT/ENHANCER-BINDING PROTEIN	10	9.21	5.20	1.77	0.07
Acetyltransferase	10	8.17	4.68	1.74	0.04
Dimethyl Sulfoxide	10	8.56	5.20	1.65	-0.05
Interleukin	10	8.23	5.00	1.65	-0.05
Chloramphenicol	10	9.06	5.58	1.62	-0.08

FIG. 27-1

Disease Progression	10	7.09	4.45	1.60	-0.10
CUTANEOUS MALIGNANT MELANOMA	10	5.95	3.81	1.56	-0.14
Retinoid	10	6.32	4.14	1.53	-0.17
Lipopolysaccharide	10	9.06	6.01	1.51	-0.19
Transferase	10	8.31	5.52	1.50	-0.20
Mitogen	10	7.09	5.02	1.41	-0.29
GASTRIC CANCER	10	4.98	3.72	1.34	-0.36
Concanavalin A	10	7.05	5.27	1.34	-0.36
Cyclophosphamide	10	6.88	5.17	1.33	-0.37
Disulfide	10	7.32	5.53	1.32	-0.38
GLIOMA OF BRAIN	10	5.15	4.03	1.28	-0.42
Conjugate	10	7.32	5.80	1.26	-0.44
Arginine	10	8.67	6.91	1.25	-0.45
Iron	10	7.98	6.79	1.18	-0.52
Glutathione	10	8.16	7.27	1.12	-0.58
Adenosine	10	6.64	6.41	1.04	-0.66
Glioma	10	4.95	4.81	1.03	-0.67
Recurrence	10	6.01	7.10	0.85	-0.85
TNF	10	4.90	6.49	0.76	-0.94
Urobilinogen	10	6.71	8.94	0.75	-0.95
Sulfate	10	5.99	8.38	0.71	-0.99
Inflammation	10	5.93	8.65	0.69	-1.01
Phosphate	10	5.99	8.97	0.67	-1.03
Ventricle	10	5.30	7.96	0.67	-1.03
Tyrosine	10	4.38	7.60	0.58	-1.12
HEPATOCELLULAR CARCINOMA	10	2.99	6.58	0.45	-1.25
Stress	10	4.57	10.33	0.44	-1.26
EGR1	9	8.73	2.43	3.60	1.90
BETA TUBULIN	9	7.83	2.49	3.15	1.45
KITLG	9	8.67	2.77	3.13	1.43
BENIGN PROSTATIC HYPERPLASIA	9	8.56	2.74	3.13	1.43
Transglutaminase	9	7.61	2.50	3.04	1.34
Progesterone Receptors	9	7.37	2.44	3.02	1.32
MDB	9	6.98	2.51	2.78	1.08
SPP1	9	6.72	2.43	2.76	1.06
ACTC	9	7.88	2.86	2.76	1.06
T-Cell Leukemia	9	7.48	2.80	2.67	0.97
Propidium	9	8.39	3.16	2.65	0.95
Ribosomal Proteins	9	7.58	2.89	2.62	0.92
Embryonal Carcinoma	9	7.11	2.74	2.59	0.89
Gastritis	9	8.22	3.17	2.59	0.89
Fucose	9	7.39	2.87	2.58	0.88
Apoprotein	9	8.02	3.24	2.47	0.77
IL3	9	8.12	3.30	2.46	0.76
IL2RA	9	8.59	3.55	2.42	0.72
Metaplasia	9	8.24	3.45	2.39	0.69
Lyase	9	6.72	2.83	2.37	0.67
GAPD	9	8.37	3.55	2.36	0.66
ACTB	9	8.24	3.50	2.36	0.66
AP4B1	9	8.19	3.59	2.28	0.58
Chronic Hepatitis	9	7.58	3.43	2.21	0.51
Bromodeoxyuridine	9	8.57	3.96	2.17	0.47

FIG. 27-2

Vaccinia	9	7.21	3.34	2.16	0.46
Fibrosarcoma	9	7.54	3.61	2.09	0.39
Mannose	9	8.52	4.13	2.06	0.36
Rhabdomyosarcoma	9	5.81	2.88	2.01	0.31
Colony-Stimulating Factors	9	7.57	3.77	2.01	0.31
Phorbol Esters	9	6.96	3.47	2.01	0.31
Biotin	9	8.23	4.14	1.99	0.29
IGF1	9	6.62	3.37	1.97	0.27
Lymphocytic Leukemia	9	7.59	3.91	1.94	0.24
Proteoglycan	9	8.23	4.29	1.92	0.22
CD44	9	5.40	2.83	1.91	0.21
AUTOIMMUNE DISEASES	9	7.56	4.04	1.87	0.17
Galactose	9	8.26	4.43	1.86	0.16
Phytohemagglutinin	9	7.85	4.21	1.86	0.16
Ornithine Decarboxylase	9	6.63	3.60	1.84	0.14
Myristate	9	7.92	4.36	1.82	0.12
INTERCELLULAR ADHESION MOLECULE 1	9	7.23	4.08	1.77	0.07
SEVERE COMBINED IMMUNODEFICIENCY 1	9	5.75	3.31	1.74	0.04
BETA SUBUNIT NERVE GROWTH FACTOR	9	7.37	4.27	1.73	0.03
Myeloid Leukemia	9	6.56	3.81	1.72	0.02
CD8A	9	7.39	4.33	1.71	0.01
Endotoxin	9	7.97	4.69	1.70	0.00
Ferritin	9	6.71	4.05	1.65	-0.05
beta-Galactosidase	9	8.54	5.21	1.64	-0.06
Forskolin	9	7.45	4.57	1.63	-0.07
CYSTIC FIBROSIS	9	7.36	4.53	1.62	-0.08
Esterase	9	7.81	4.82	1.62	-0.08
Silver	9	8.56	5.32	1.61	-0.09
Nitric-Oxide Synthase	9	7.62	4.74	1.61	-0.09
Sialic Acids	9	6.74	4.20	1.60	-0.10
SYSTEMIC LUPUS ERYTHEMATOSUS	9	7.38	4.63	1.59	-0.11
Valine	9	8.16	5.14	1.59	-0.11
Iodide	9	7.47	4.71	1.59	-0.11
PCNA	9	5.39	3.39	1.59	-0.11
VEGF	9	4.92	3.14	1.57	-0.13
Antimetabolite	9	7.71	4.93	1.56	-0.14
Hydrocortisone	9	7.20	4.62	1.56	-0.14
IL4	9	6.82	4.39	1.55	-0.15
Tamoxifen	9	5.52	3.64	1.51	-0.19
Proline	9	8.40	5.62	1.49	-0.21
Lactate	9	8.34	5.60	1.49	-0.21
Luciferase	9	7.48	5.05	1.48	-0.22
LMNA	9	8.36	5.68	1.47	-0.23
Isoenzyme	9	6.98	4.79	1.46	-0.24
Tryptophan	9	8.26	5.69	1.45	-0.25
phorbol ester	9	6.90	4.76	1.45	-0.25
Guanosine	9	6.91	4.79	1.44	-0.26
TF	9	6.81	4.77	1.43	-0.27
Paraffin	9	6.78	4.79	1.41	-0.29
Anemia	9	7.73	5.51	1.40	-0.30
PTH	9	6.15	4.49	1.37	-0.33
Cyclosporin	9	8.40	6.20	1.36	-0.34

FIG. 27-3

Estradiol	9	6.96	5.27	1.32	-0.38
Angiogenesis	9	5.57	4.36	1.28	-0.42
Glycerol	9	8.33	6.55	1.27	-0.43
Androgen	9	6.16	4.88	1.26	-0.44
Nucleoside	9	5.98	4.86	1.23	-0.47
CALCA	9	5.34	4.37	1.22	-0.48
Cystadenoma	9	6.06	5.06	1.20	-0.50
Toxin	9	7.10	5.96	1.19	-0.51
Glycine	9	7.98	6.71	1.19	-0.51
Dopamine	9	6.82	5.74	1.19	-0.51
Phosphatidylinositol	9	6.15	5.20	1.18	-0.52
Thrombosis	9	5.95	5.12	1.16	-0.54
Proton	9	6.84	6.13	1.12	-0.58
Testosterone	9	6.24	5.73	1.09	-0.61
Heparin	9	6.63	6.11	1.09	-0.61
Serum Albumin	9	7.22	6.73	1.07	-0.63
Lysine	9	7.38	6.91	1.07	-0.63
Cytochrome	9	6.91	6.60	1.05	-0.65
Cyclic AMP	9	6.15	5.91	1.04	-0.66
Glucocorticoid	9	5.51	5.39	1.02	-0.68
Alanine	9	7.33	7.18	1.02	-0.68
Nitric Oxide	9	5.65	5.90	0.96	-0.74
Lactate Dehydrogenase	9	5.63	6.02	0.93	-0.77
BETA-1 TRANSFORMING GROWTH FACTOR	9	4.40	4.75	0.93	-0.77
Fibrosis	9	5.91	6.38	0.93	-0.77
Interferon	9	5.40	5.89	0.92	-0.78
Genomic Instability	9	4.49	4.92	0.91	-0.79
Leukemia	9	6.92	7.60	0.91	-0.79
ALB	9	6.38	7.08	0.90	-0.80
Methylation	9	4.96	5.86	0.85	-0.85
Ethanol	9	5.89	7.31	0.81	-0.89
Phospholipid	9	5.63	7.26	0.78	-0.92
IL6	9	3.80	5.64	0.67	-1.03
Prostaglandin	9	4.39	6.62	0.66	-1.04
NB	9	3.24	5.60	0.58	-1.12
p53	8	7.47	1.83	4.07	2.37
ALPHA	8	7.72	2.24	3.45	1.75
LIF	8	7.52	2.19	3.43	1.73
SLC2A1	8	6.61	2.04	3.23	1.53
KRT10	8	5.98	1.87	3.19	1.49
MAPK3	8	7.57	2.58	2.94	1.24
Cyclin-Dependent Kinases	8	6.32	2.16	2.92	1.22
Fish Oils	8	7.10	2.49	2.85	1.15
CD28	8	6.71	2.36	2.85	1.15
F9	8	6.98	2.48	2.82	1.12
Phalloidine	8	6.17	2.20	2.81	1.11
FGF1	8	6.24	2.25	2.77	1.07
Quercetin	8	7.61	2.78	2.74	1.04
COLONY-STIMULATING FACTOR 1	8	6.92	2.53	2.74	1.04
Interleukin-3	8	7.12	2.61	2.73	1.03
SUPEROXIDE DISMUTASE 2	8	6.89	2.54	2.71	1.01
B-Cell Lymphoma	8	6.74	2.51	2.69	0.99

FIG. 27-4

CDKN2D	8	6.86	2.56	2.68	0.98
Oligodendroglioma	8	7.79	2.95	2.64	0.94
T-Cell Lymphoma	8	7.60	2.89	2.63	0.93
Fluorescein-5-isothiocyanate	8	6.68	2.58	2.59	0.89
HXB	8	5.99	2.34	2.56	0.86
Kallikrein	8	7.27	2.86	2.54	0.84
TYPE I NEUROFIBROMATOSIS	8	6.95	2.74	2.54	0.84
DNTT	8	6.56	2.61	2.51	0.81
Medroxyprogesterone	8	6.04	2.41	2.51	0.81
CDK2	8	5.99	2.40	2.49	0.79
C RECEPTOR-TYPE PROTEIN-TYROSINE PHOSPHATASE	8	7.14	2.86	2.49	0.79
Nevus	8	5.70	2.29	2.49	0.79
Tunicamycin	8	7.31	2.95	2.47	0.77
Diabetic Retinopathy	8	6.20	2.52	2.46	0.76
SELL	8	6.96	2.85	2.44	0.74
Spermidine	8	7.93	3.30	2.40	0.70
Papilloma	8	7.24	3.01	2.40	0.70
Glycopeptide	8	7.30	3.07	2.38	0.68
NGFR	8	6.52	2.76	2.37	0.67
ANTITHROMBIN III DEFICIENCY	8	7.34	3.12	2.36	0.66
Interleukin-4	8	6.98	2.96	2.36	0.66
CD34	8	5.98	2.61	2.30	0.60
Spermine	8	7.93	3.46	2.29	0.59
TFRC	8	7.23	3.16	2.29	0.59
Phosphopeptide	8	6.03	2.64	2.28	0.58
IFNG	8	7.24	3.20	2.27	0.57
Metallothionein	8	7.34	3.26	2.25	0.55
AR	8	6.43	2.95	2.18	0.48
GLUCOCORTICOID RECEPTOR	8	7.24	3.33	2.17	0.47
NEUROD1	8	7.47	3.44	2.17	0.47
SARCOIDOSIS	8	7.18	3.34	2.15	0.45
Glycoconjugate	8	6.46	3.02	2.14	0.44
GFAP	8	6.53	3.07	2.13	0.43
Hypercholesterolemia	8	6.85	3.24	2.11	0.41
Triiodothyronine	8	7.59	3.61	2.10	0.40
TG	8	6.35	3.10	2.05	0.35
Bacteriocin	8	7.30	3.57	2.05	0.35
alcohol consumption	8	5.92	2.91	2.04	0.34
Irritant	8	5.96	2.95	2.02	0.32
Ulcerative Colitis	8	7.41	3.67	2.02	0.32
TIMP1	8	5.10	2.53	2.02	0.32
ACUTE LYMPHOBLASTIC LEUKEMIA	8	7.21	3.59	2.01	0.31
Retinal Pigments	8	7.07	3.60	1.96	0.26
Blood Groups	8	6.93	3.53	1.96	0.26
NON-HODGKIN LYMPHOMA	8	6.16	3.15	1.95	0.25
CTSD	8	5.69	2.93	1.94	0.24
stress-induced	8	7.47	3.88	1.92	0.22
Ionomycin	8	6.56	3.42	1.92	0.22
Genetic Markers	8	6.97	3.65	1.91	0.21
bA430M15.1	8	7.39	3.92	1.89	0.19
Glycol	8	7.00	3.71	1.89	0.19
Neuraminidase	8	7.20	3.83	1.88	0.18

FIG. 27-5

Hyaluronic Acid	8	5.95	3.17	1.88	0.18
Chorionic Gonadotropins	8	6.48	3.45	1.88	0.18
Genistein	8	6.58	3.51	1.87	0.17
Ovalbumin	8	6.90	3.76	1.84	0.14
Lactic Acid	8	6.73	3.69	1.82	0.12
COLONY-STIMULATING FACTOR 2	8	6.40	3.52	1.82	0.12
Glycosaminoglycan	8	7.46	4.17	1.79	0.09
CCND1	8	4.55	2.56	1.78	0.08
Interleukin-12	8	5.40	3.05	1.77	0.07
Guanine Nucleotides	8	6.33	3.58	1.77	0.07
Vitamin D	8	6.71	3.81	1.76	0.06
SELE	8	5.06	2.87	1.76	0.06
Teratoma	8	5.30	3.01	1.76	0.06
Creatine	8	7.22	4.10	1.76	0.06
Diphosphate	8	5.84	3.33	1.75	0.05
Thyroxine	8	7.35	4.20	1.75	0.05
EPO	8	6.80	3.88	1.75	0.05
Psoriasis	8	6.77	3.88	1.75	0.05
Polyamine	8	6.24	3.57	1.75	0.05
MAPT	8	6.79	3.91	1.74	0.04
MAPK1	8	6.58	3.80	1.73	0.03
Ion Channels	8	6.13	3.55	1.73	0.03
Vinblastine	8	6.03	3.50	1.72	0.02
Nifedipine	8	7.26	4.25	1.71	0.01
beta-catenin	8	3.82	2.26	1.69	-0.01
Neomycin	8	7.16	4.28	1.67	-0.03
Recombinant Proteins	8	6.36	3.84	1.66	-0.04
Thiomalate	8	7.37	4.49	1.64	-0.06
HIV Infection	8	7.12	4.36	1.64	-0.06
Endonuclease	8	7.29	4.51	1.62	-0.08
Isoleucine	8	7.26	4.53	1.60	-0.10
Tubulin	8	5.74	3.59	1.60	-0.10
Pertussis Toxins	8	6.16	3.86	1.59	-0.11
Acetone	8	7.05	4.43	1.59	-0.11
MN1	8	4.97	3.14	1.58	-0.12
Imidazole	8	6.49	4.14	1.57	-0.13
Interleukin-1	8	7.47	4.82	1.55	-0.15
LYZ	8	7.21	4.66	1.55	-0.15
Purine	8	6.89	4.47	1.54	-0.16
Adenosine Monophosphate	8	5.89	3.82	1.54	-0.16
CAT	8	7.82	5.14	1.52	-0.18
Sepharose	8	7.33	4.86	1.51	-0.19
Hyperglycemia	8	6.23	4.22	1.48	-0.22
Agglutinin	8	6.15	4.18	1.47	-0.23
Interleukin-6	8	6.57	4.48	1.47	-0.23
Oligosaccharide	8	6.92	4.72	1.47	-0.23
Phospholipase C	8	6.56	4.52	1.45	-0.25
GNRH1	8	5.58	3.86	1.45	-0.25
Isoproterenol	8	6.27	4.35	1.44	-0.26
BDK	8	5.71	3.96	1.44	-0.26
Fibrinogen	8	7.07	4.92	1.44	-0.26
Fluorescein	8	7.33	5.11	1.44	-0.26

FIG. 27-6

Neuropeptide	8	6.39	4.48	1.43	-0.27
Inositol	8	6.32	4.44	1.42	-0.28
Peroxidase	8	7.57	5.34	1.42	-0.28
Calmodulin	8	6.33	4.57	1.38	-0.32
F2	8	6.15	4.45	1.38	-0.32
BLADDER CANCER	8	4.24	3.10	1.37	-0.33
Casein	8	6.41	4.70	1.36	-0.34
Transaminase	8	6.71	4.94	1.36	-0.34
Matrix Metalloproteinases	8	3.95	2.94	1.34	-0.36
Bromide	8	7.47	5.58	1.34	-0.36
Mucin	8	4.89	3.70	1.32	-0.38
HGF	8	3.97	3.00	1.32	-0.38
Aneuploidy	8	4.40	3.33	1.32	-0.38
Glutamine	8	7.65	5.81	1.32	-0.38
Thymidine	8	7.00	5.37	1.30	-0.40
Phosphatidylcholine	8	6.35	4.89	1.30	-0.40
ALPHA-1 INTERFERON	8	5.24	4.08	1.28	-0.42
Phenylalanine	8	6.57	5.12	1.28	-0.42
Gold	8	7.23	5.67	1.28	-0.42
Citrate	8	6.71	5.34	1.26	-0.44
Herpes Simplex	8	6.32	5.04	1.25	-0.45
Leucine	8	7.55	6.03	1.25	-0.45
FGF	8	5.92	4.76	1.24	-0.46
Bone Resorption	8	4.20	3.40	1.24	-0.46
Arachidonic Acid	8	6.57	5.33	1.23	-0.47
Creatinine	8	7.37	6.12	1.20	-0.50
tyrosine phosphorylation	8	5.58	4.67	1.20	-0.50
RA	8	6.64	5.58	1.19	-0.51
Anion	8	7.81	6.58	1.19	-0.51
Adenine	8	6.12	5.16	1.19	-0.51
blood alcohol	8	5.20	4.42	1.18	-0.52
Catecholamine	8	6.37	5.51	1.16	-0.54
Serotonin	8	6.73	5.86	1.15	-0.55
Hepatitis	8	6.23	5.42	1.15	-0.55
Fever	8	7.25	6.33	1.15	-0.55
Plasminogen Activators	8	4.80	4.21	1.14	-0.56
FGF2	8	4.41	3.94	1.12	-0.58
Histidine	8	6.58	5.90	1.11	-0.59
Atrophy	8	7.75	6.99	1.11	-0.59
Doxorubicin	8	5.58	5.10	1.09	-0.61
Acetylcholine	8	6.37	5.92	1.08	-0.62
Methotrexate	8	5.03	4.71	1.07	-0.63
PRL	8	5.51	5.27	1.04	-0.66
Hydrogen	8	6.74	6.46	1.04	-0.66
APOLIPOPROTEIN	8	6.58	6.41	1.03	-0.67
Arthritis	8	5.18	5.16	1.00	-0.70
Myocardial Infarction	8	4.98	5.05	0.99	-0.71
Zinc	8	6.81	7.67	0.89	-0.81
Diabetes Mellitus	8	5.16	6.19	0.83	-0.87
Potassium	8	6.13	7.40	0.83	-0.87
Indomethacin	8	4.40	5.60	0.79	-0.91
Edema	8	4.48	6.53	0.69	-1.01

FIG. 27-7



Hypertension	8	3.41	6.92	0.49	-1.21
ERBB4	7	6.06	1.31	4.63	2.93
ERBB3	7	6.38	1.40	4.55	2.85
TOP2A	7	6.00	1.32	4.54	2.84
SPARC	7	6.65	1.75	3.79	2.09
Ecdysone	7	5.86	1.57	3.74	2.04
CADHERIN 2	7	6.23	1.69	3.69	1.99
KRT14	7	6.16	1.70	3.62	1.92
Caveolin	7	6.41	1.79	3.59	1.89
IGF2	7	6.38	1.86	3.44	1.74
GAMMA	7	6.50	1.92	3.39	1.69
Ependymoma	7	6.03	1.87	3.22	1.52
ALPHA-1 GAP JUNCTION PROTEIN	7	6.36	2.02	3.15	1.45
Fibronectin Receptors	7	5.61	1.79	3.14	1.44
Retinoblastoma Protein	7	6.57	2.10	3.13	1.43
CSF1	7	6.55	2.09	3.13	1.43
KRT8	7	6.20	1.98	3.12	1.42
ARHA	7	6.15	1.98	3.11	1.41
IL7	7	6.56	2.11	3.10	1.40
PTK2B	7	6.94	2.25	3.08	1.38
F2R	7	6.10	2.00	3.05	1.35
Neuroectodermal Tumors	7	6.30	2.10	3.01	1.31
Leiomyoma	7	6.82	2.28	3.00	1.30
CCNA2	7	6.39	2.13	3.00	1.30
FGFR2	7	6.16	2.08	2.96	1.26
ESR2	7	5.47	1.85	2.96	1.26
Laminin Receptors	7	4.98	1.69	2.94	1.24
IL13	7	6.54	2.23	2.94	1.24
Digoxigenin	7	5.95	2.02	2.94	1.24
VCL	7	6.24	2.13	2.92	1.22
TYRO3	7	5.81	2.03	2.86	1.16
TNFRSF8	7	5.78	2.03	2.84	1.14
Annexin	7	6.02	2.13	2.82	1.12
Medullary Carcinoma	7	5.59	1.99	2.81	1.11
CHGA	7	6.58	2.34	2.81	1.11
CDKL1	7	6.91	2.48	2.79	1.09
SHC TRANSFORMING PROTEIN	7	5.87	2.12	2.78	1.08
OVCE	7	5.13	1.85	2.77	1.07
Papillary Carcinoma	7	5.57	2.02	2.76	1.06
CCNE1	7	5.50	1.99	2.76	1.06
Hepatoblastoma	7	6.36	2.32	2.74	1.04
BCL2L1	7	6.47	2.36	2.74	1.04
Monokine	7	6.19	2.27	2.73	1.03
CCNB1	7	6.34	2.33	2.72	1.02
Ricin	7	6.13	2.28	2.69	0.99
Sphingosine	7	6.96	2.63	2.64	0.94
Calpain	7	6.76	2.57	2.63	0.93
XPR1	7	6.47	2.49	2.60	0.90
JAK2	7	4.91	1.89	2.60	0.90
SYNAPTOTAGMIN 1	7	6.78	2.62	2.59	0.89
Lovastatin	7	6.20	2.41	2.57	0.87
VDR	7	5.36	2.11	2.55	0.85

FIG. 27-8

Interleukin-10	7	6.38	2.51	2.54	0.84
BDNF	7	5.87	2.31	2.54	0.84
Cytochalasin D	7	6.72	2.65	2.54	0.84
Cytochalasin	7	5.72	2.26	2.53	0.83
LEUKOCYTE ANTIGEN CD23	7	5.52	2.18	2.53	0.83
Heterochromatin	7	6.12	2.42	2.53	0.83
Peanut Agglutinin	7	5.65	2.25	2.51	0.81
RNA Probes	7	5.11	2.05	2.49	0.79
CDC2	7	6.46	2.60	2.49	0.79
Glycosyltransferase	7	5.74	2.31	2.49	0.79
Liposarcoma	7	4.72	1.90	2.49	0.79
PLATELET-ENDOTHELIAL CELL ADHESION MOLECULE 1	7	5.23	2.12	2.47	0.77
HEAT-SHOCK 27-KD PROTEIN 1	7	4.94	2.01	2.45	0.75
NF-kappa B	7	6.95	2.85	2.44	0.74
Phospholipase D	7	6.37	2.62	2.43	0.73
Antigen Receptors	7	6.46	2.68	2.41	0.71
Antisense RNA	7	6.55	2.72	2.41	0.71
KAZAL-TYPE SERINE PROTEASE INHIBITOR 1	7	6.22	2.59	2.40	0.70
Leucine zipper	7	6.38	2.66	2.40	0.70
Androgen Receptors	7	4.79	2.01	2.38	0.68
RDC1	7	6.92	2.91	2.38	0.68
Developmental role	7	6.50	2.75	2.37	0.67
CDKN1A	7	5.65	2.42	2.34	0.64
SUPERFAMILY	7	6.38	2.73	2.34	0.64
Raffinose	7	6.82	2.94	2.32	0.62
nuclear translocation	7	6.99	3.03	2.31	0.61
JUN	7	6.82	2.99	2.28	0.58
ACUTE MYELOGENOUS LEUKEMIA	7	6.09	2.67	2.28	0.58
ADCYAP1	7	4.39	1.93	2.27	0.57
Phosphatidic Acids	7	6.68	2.95	2.27	0.57
Cachexia	7	6.34	2.80	2.26	0.56
Leiomyosarcoma	7	4.98	2.21	2.25	0.55
TGFA	7	5.92	2.62	2.25	0.55
Phosphorylase	7	6.17	2.78	2.22	0.52
Calcium-Binding Proteins	7	6.48	2.92	2.22	0.52
Pyruvate Kinase	7	6.54	2.96	2.21	0.51
Arsenite	7	5.38	2.45	2.20	0.50
CD14	7	6.17	2.81	2.19	0.49
Ceramide	7	6.82	3.11	2.19	0.49
CYP19	7	5.55	2.54	2.19	0.49
Chimeric Proteins	7	5.63	2.58	2.18	0.48
Liver Extracts	7	5.46	2.51	2.18	0.48
MuLV	7	5.57	2.57	2.17	0.47
Plasmacytoma	7	5.53	2.55	2.17	0.47
SURFACE ANTIGEN 6	7	5.68	2.63	2.16	0.46
DES	7	6.37	2.96	2.15	0.45
PML	7	6.82	3.18	2.15	0.45
LPL	7	6.62	3.09	2.14	0.44
Hexokinase	7	6.05	2.84	2.13	0.43
GTP-Binding Proteins	7	5.30	2.49	2.12	0.42
VTN	7	5.16	2.44	2.12	0.42
Cystitis	7	5.54	2.63	2.11	0.41

FIG. 27-9

Okadaic Acid	7	6.54	3.11	2.10	0.40
IL5	7	6.19	2.95	2.10	0.40
PROSTATE-SPECIFIC ACID PHOSPHATASE	7	3.87	1.84	2.10	0.40
PROC	7	6.67	3.19	2.09	0.39
MAPK14	7	7.00	3.35	2.09	0.39
Peptic Ulcer	7	6.32	3.03	2.08	0.38
VCAM1	7	5.62	2.70	2.08	0.38
PANCREATIC CARCINOMA	7	5.55	2.67	2.08	0.38
Protein-Tyrosine Kinase	7	5.82	2.80	2.08	0.38
PLP2	7	6.05	2.93	2.07	0.37
HSPA4	7	6.70	3.26	2.05	0.35
Endothelin-1	7	6.86	3.36	2.04	0.34
Gadolinium	7	5.98	2.93	2.04	0.34
Saponin	7	5.70	2.81	2.03	0.33
IGSF3	7	6.01	2.96	2.03	0.33
H4F2	7	5.95	2.94	2.03	0.33
Recombinant DNA	7	6.64	3.29	2.02	0.32
Holoenzyme	7	6.20	3.07	2.02	0.32
potassium channel	7	5.61	2.78	2.02	0.32
CD2	7	5.66	2.82	2.01	0.31
Trisomy	7	6.05	3.06	1.97	0.27
ATOD	7	5.95	3.01	1.97	0.27
Cyclin	7	5.97	3.03	1.97	0.27
ELN	7	5.98	3.05	1.96	0.26
Chondroitin Sulfates	7	5.81	2.96	1.96	0.26
Malondialdehyde	7	6.59	3.37	1.95	0.25
Xanthine Oxidase	7	6.74	3.46	1.95	0.25
LTF	7	5.92	3.04	1.94	0.24
Phosphotransferase	7	5.55	2.85	1.94	0.24
RCD-8	7	6.36	3.27	1.94	0.24
Choriocarcinoma	7	5.52	2.84	1.94	0.24
Osteolysis	7	3.88	2.00	1.94	0.24
Hyperlipidemia	7	6.14	3.17	1.94	0.24
beta 2-Microglobulin	7	6.60	3.42	1.93	0.23
UBIQUITIN	7	6.56	3.41	1.93	0.23
proline-rich	7	6.40	3.32	1.93	0.23
Brefeldin A	7	5.23	2.72	1.92	0.22
Androstenedione	7	5.01	2.64	1.90	0.20
Phenylmethylsulfonyl Fluoride	7	5.18	2.74	1.89	0.19
Rheumatic Disease	7	5.44	2.88	1.89	0.19
Biological Markers	7	4.56	2.42	1.88	0.18
Corticotropin	7	5.90	3.17	1.86	0.16
INSULIN-LIKE GROWTH FACTOR II	7	4.97	2.68	1.86	0.16
APOB	7	5.49	2.98	1.84	0.14
cardiac hypertrophy	7	6.23	3.39	1.84	0.14
TAGLN	7	6.38	3.47	1.84	0.14
Bromocriptine	7	5.37	2.94	1.83	0.13
Ibuprofen	7	6.08	3.34	1.82	0.12
Hypoxanthine	7	6.20	3.41	1.82	0.12
Thyrotropin	7	5.64	3.11	1.81	0.11
MBP	7	5.95	3.30	1.80	0.10
IL10	7	6.82	3.81	1.79	0.09

FIG. 27-10

Phosphotyrosine	7	5.40	3.02	1.79	0.09
Estrone	7	4.84	2.70	1.79	0.09
Hyperthyroidism	7	6.40	3.58	1.79	0.09
Benzoate	7	5.99	3.35	1.79	0.09
RTKN	7	5.49	3.08	1.78	0.08
Butyrate	7	6.79	3.82	1.78	0.08
ADA	7	5.62	3.16	1.78	0.08
Thymine	7	5.98	3.36	1.78	0.08
Single-Stranded DNA	7	5.56	3.13	1.77	0.07
Diethylstilbestrol	7	4.99	2.83	1.76	0.06
Lipoxygenase	7	6.16	3.49	1.76	0.06
Sterol	7	6.22	3.53	1.76	0.06
Trypan Blue	7	6.32	3.59	1.76	0.06
Eicosanoid	7	6.16	3.51	1.76	0.06
Ribulose-Bisphosphate Carboxylase	7	5.70	3.26	1.75	0.05
Hydroxyl Radical	7	6.57	3.78	1.74	0.04
S14	7	6.91	3.99	1.73	0.03
Polyethylene	7	6.07	3.52	1.72	0.02
Sex Hormones	7	5.13	2.99	1.72	0.02
Xanthine	7	5.96	3.47	1.72	0.02
Oxytocin	7	5.66	3.31	1.71	0.01
Quinacrine	7	5.08	2.97	1.71	0.01
C-Reactive Protein	7	6.15	3.62	1.70	0.00
Lactose	7	6.37	3.76	1.69	-0.01
Protease Inhibitors	7	6.89	4.08	1.69	-0.01
Carrier Proteins	7	5.97	3.54	1.69	-0.01
Oxidoreductase	7	6.32	3.76	1.68	-0.02
5'-Nucleotidase	7	4.91	2.92	1.68	-0.02
Growth Inhibitors	7	5.41	3.24	1.67	-0.03
Phenytoin	7	6.34	3.80	1.67	-0.03
F8C	7	5.49	3.30	1.66	-0.04
Inositol Phosphates	7	5.27	3.18	1.66	-0.04
Hydroxyurea	7	5.55	3.35	1.66	-0.04
Thymidine Kinase	7	5.80	3.51	1.65	-0.05
VWF	7	5.50	3.33	1.65	-0.05
Adhesions	7	6.33	3.84	1.65	-0.05
Cobalt	7	6.33	3.86	1.64	-0.06
Infertility	7	5.96	3.66	1.63	-0.07
Nicotine	7	6.34	3.90	1.63	-0.07
Adenine Nucleotides	7	5.39	3.31	1.63	-0.07
Serine protease	7	5.92	3.68	1.61	-0.09
Succinate	7	6.80	4.27	1.59	-0.11
Glomerulonephritis	7	6.34	3.98	1.59	-0.11
Horseradish Peroxidase	7	6.37	4.01	1.59	-0.11
Phosphatidylethanolamine	7	5.96	3.76	1.59	-0.11
Nitrite	7	6.37	4.03	1.58	-0.12
Nephritis	7	5.36	3.40	1.58	-0.12
PTHLH	7	3.58	2.28	1.57	-0.13
Starch	7	5.95	3.79	1.57	-0.13
Aspartic Acid	7	6.62	4.24	1.56	-0.14
Peroxide	7	5.49	3.52	1.56	-0.14
Oxidant	7	6.82	4.37	1.56	-0.14

FIG. 27-11

Polyphosphate	7	5.39	3.46	1.56	-0.14
Platinum	7	5.26	3.39	1.55	-0.15
Oral Contraceptives	7	4.81	3.10	1.55	-0.15
Creatine Kinase	7	6.54	4.25	1.54	-0.16
MUCOPOLYSACCHARIDOSIS TYPE VII	7	6.47	4.23	1.53	-0.17
Isothiocyanate	7	5.63	3.71	1.52	-0.18
Angiotensin	7	6.22	4.20	1.48	-0.22
Heme	7	6.19	4.19	1.48	-0.22
Eosinophilia	7	5.49	3.75	1.47	-0.23
Liver Cirrhosis	7	5.62	3.84	1.46	-0.24
REN	7	5.86	4.02	1.46	-0.24
Chronic Disease	7	5.56	3.84	1.45	-0.25
Vitamin A	7	5.52	3.82	1.44	-0.26
Polysaccharide	7	6.55	4.56	1.44	-0.26
Oxide	7	6.41	4.47	1.43	-0.27
Sclerosis	7	6.77	4.76	1.42	-0.28
Charcoal	7	5.18	3.65	1.42	-0.28
Hypothyroidism	7	6.09	4.29	1.42	-0.28
Tetrodotoxin	7	4.73	3.34	1.41	-0.29
Vitamin E	7	5.91	4.18	1.41	-0.29
CADHERIN 1	7	3.63	2.58	1.41	-0.29
Erythema	7	5.91	4.20	1.41	-0.29
Dextran	7	6.40	4.55	1.41	-0.29
Vanadate	7	4.32	3.08	1.40	-0.30
Adenylate Cyclase	7	6.79	4.86	1.40	-0.30
HCS	7	6.20	4.44	1.40	-0.30
Plasmin	7	4.37	3.14	1.39	-0.31
Silicone	7	4.91	3.53	1.39	-0.31
BETA-2-ADRENERGIC RECEPTOR	7	4.95	3.57	1.39	-0.31
Amyloid	7	5.98	4.32	1.38	-0.32
VIP	7	4.98	3.62	1.38	-0.32
Selenium	7	5.13	3.74	1.37	-0.33
Aspirin	7	6.41	4.73	1.36	-0.34
APG-1	7	5.65	4.18	1.35	-0.35
PLASMINOGEN ACTIVATOR INHIBITOR 1	7	3.97	2.94	1.35	-0.35
Bilirubin	7	6.17	4.58	1.35	-0.35
Superoxide Dismutase	7	6.91	5.15	1.34	-0.36
Peritonitis	7	4.99	3.75	1.33	-0.37
Proteinuria	7	5.91	4.46	1.32	-0.38
congestive heart failure	7	5.38	4.07	1.32	-0.38
Phosphoru	7	6.50	4.92	1.32	-0.38
Pancreatitis	7	5.39	4.09	1.32	-0.38
F3	7	4.80	3.65	1.31	-0.39
Hydrogen Peroxide	7	6.82	5.21	1.31	-0.39
Methanol	7	6.86	5.25	1.31	-0.39
Superoxide	7	6.99	5.36	1.31	-0.39
Acetic Acid	7	6.33	4.85	1.30	-0.40
CFDP1	7	5.55	4.28	1.30	-0.40
Dehydration	7	5.96	4.60	1.29	-0.41
Cataract	7	5.82	4.50	1.29	-0.41
Sodium Chloride	7	5.56	4.32	1.29	-0.41
AFP	7	4.43	3.46	1.28	-0.42

FIG. 27-12

Ichthyosis	7	5.98	4.69	1.28	-0.42
Ammonia	7	5.63	4.43	1.27	-0.43
Sepsis	7	6.90	5.42	1.27	-0.43
Crystallin	7	6.32	5.00	1.27	-0.43
Iodine	7	5.58	4.42	1.26	-0.44
GLUTATHIONE PEROXIDASE	7	4.57	3.66	1.25	-0.45
Inversion	7	6.20	4.97	1.25	-0.45
Amylase	7	4.96	3.98	1.25	-0.45
Infarction	7	5.74	4.65	1.23	-0.47
IF	7	4.58	3.75	1.22	-0.48
Insulin Resistance	7	4.12	3.42	1.20	-0.50
RETINOBLASTOMA	7	3.96	3.29	1.20	-0.50
Copper	7	6.52	5.45	1.20	-0.50
Pleural Effusion	7	4.32	3.63	1.19	-0.51
Globulin	7	4.94	4.20	1.18	-0.52
INSULIN-LIKE GROWTH FACTOR I	7	4.82	4.16	1.16	-0.54
Cortisone	7	5.96	5.18	1.15	-0.55
Mitomycin	7	4.40	3.85	1.14	-0.56
Vincristine	7	4.38	3.90	1.13	-0.57
Sulfur	7	4.80	4.28	1.12	-0.58
ANGIOTENSIN I	7	4.99	4.46	1.12	-0.58
CERVICAL CANCER	7	3.16	2.82	1.12	-0.58
Triglyceride	7	5.97	5.38	1.11	-0.59
Phospholipase	7	5.93	5.35	1.11	-0.59
SST	7	4.93	4.46	1.10	-0.60
Paralysis	7	5.15	4.68	1.10	-0.60
Carbachol	7	4.11	3.77	1.09	-0.61
Thrombocytopenia	7	5.16	4.74	1.09	-0.61
Prednisolone	7	5.13	4.74	1.08	-0.62
Oil	7	5.83	5.52	1.06	-0.64
Carbon	7	6.95	6.77	1.03	-0.67
Dithiothreitol	7	4.91	4.82	1.02	-0.68
INTERLEUKIN 1-BETA	7	5.93	5.87	1.01	-0.69
Propranolol	7	4.89	4.86	1.01	-0.69
gamma-Aminobutyric Acid	7	4.46	4.57	0.98	-0.72
Histamine	7	5.65	5.81	0.97	-0.73
Nausea	7	4.91	5.09	0.96	-0.74
Adenosine Diphosphate	7	5.40	5.63	0.96	-0.74
Fibrin	7	4.39	4.60	0.96	-0.74
Magnesium	7	5.55	5.85	0.95	-0.75
Glutamate	7	5.68	6.02	0.94	-0.76
Hemoglobin	7	5.97	6.44	0.93	-0.77
Vomiting	7	5.09	5.50	0.92	-0.78
Hemorrhage	7	5.44	6.01	0.91	-0.79
Nitrogen	7	6.75	7.51	0.90	-0.80
IL8	7	3.51	3.94	0.89	-0.81
Atrium	7	4.78	5.54	0.86	-0.84
Glycogen	7	4.32	5.05	0.86	-0.84
Ester	7	5.83	7.07	0.82	-0.88
Tuberculosis	7	4.17	5.06	0.82	-0.88
Thyroid Hormones	7	4.00	4.89	0.82	-0.88
Ascites	7	3.99	5.43	0.74	-0.96

FIG. 27-13

Cholesterol	7	5.00	7.41	0.67	-1.03
Sucrose	7	4.51	6.73	0.67	-1.03
Pneumonia	7	4.07	6.36	0.64	-1.06
IL1A	7	2.93	5.14	0.57	-1.13
FGF-3	6	5.04	1.18	4.26	2.56
STAT5B	6	5.35	1.38	3.88	2.18
HIF1A	6	5.52	1.44	3.83	2.13
Neuregulin	6	5.13	1.34	3.82	2.12
EIF4E	6	5.79	1.54	3.77	2.07
Thrombin Receptors	6	5.49	1.47	3.74	2.04
CADHERIN 3	6	4.98	1.33	3.73	2.03
Hemangioblastoma	6	5.59	1.51	3.69	1.99
ALPHA-1 THYROID HORMONE RECEPTOR	6	5.15	1.40	3.67	1.97
TIMP3	6	5.56	1.55	3.60	1.90
SOD2	6	4.78	1.34	3.57	1.87
Nodular Goiter	6	5.13	1.47	3.48	1.78
Ki-67 Antigen	6	5.99	1.74	3.45	1.75
ANXA1	6	5.47	1.60	3.42	1.72
MYB-BINDING PROTEIN 1A	6	4.71	1.41	3.34	1.64
Pleomorphic Adenoma	6	5.50	1.67	3.29	1.59
ITGB3	6	5.20	1.59	3.28	1.58
JAK1	6	5.22	1.60	3.27	1.57
OSM	6	5.55	1.70	3.26	1.56
DEAD/H BOX 5	6	5.66	1.74	3.26	1.56
NME1	6	4.62	1.42	3.26	1.56
PRLR	6	5.16	1.60	3.23	1.53
CONGENITAL ADRENAL HYPERPLASIA	6	4.61	1.46	3.15	1.45
NTRK3	6	4.70	1.51	3.12	1.42
TRANSCRIPTION FACTOR Sp1	6	5.65	1.82	3.11	1.41
NOL1	6	5.55	1.81	3.06	1.36
M6PR	6	5.10	1.69	3.02	1.32
FOSL1	6	4.64	1.54	3.01	1.31
IL15	6	5.45	1.81	3.00	1.30
E2F1	6	5.34	1.78	3.00	1.30
CSF1R	6	5.43	1.83	2.98	1.28
CDC25C	6	4.88	1.64	2.97	1.27
CCND2	6	4.67	1.57	2.97	1.27
Prolactinoma	6	5.58	1.88	2.96	1.26
CDC42	6	5.74	1.94	2.95	1.25
FGF7	6	5.63	1.91	2.95	1.25
SDC1	6	5.10	1.75	2.91	1.21
HEAD AND NECK SQUAMOUS CELL CARCINOMA	6	4.55	1.57	2.91	1.21
STAT1	6	5.81	2.00	2.90	1.20
Mifepristone	6	5.07	1.75	2.90	1.20
SLC4A1	6	5.78	2.00	2.89	1.19
ITGB1	6	5.80	2.02	2.88	1.18
CDK6	6	4.32	1.50	2.87	1.17
Neuroendocrine Tumors	6	5.13	1.79	2.87	1.17
PXN	6	5.16	1.81	2.86	1.16
CDKN1B	6	5.34	1.87	2.86	1.16
LGALS3	6	4.80	1.70	2.83	1.13
IVL	6	5.39	1.91	2.82	1.12

FIG. 27-14

BURKITT LYMPHOMA	6	5.71	2.02	2.82	1.12
Chemokine Receptors	6	5.99	2.12	2.82	1.12
CSH1	6	5.88	2.09	2.82	1.12
PRECOCIOUS PUBERTY	6	5.04	1.79	2.81	1.11
Inhibin	6	5.80	2.08	2.79	1.09
UVEAL MELANOMA	6	4.33	1.56	2.77	1.07
RASA1	6	5.51	1.99	2.77	1.07
CYTOPLASMIC PROTEIN-TYROSINE KINASE	6	5.83	2.11	2.76	1.06
Caspase 1	6	5.02	1.83	2.75	1.05
Fibroadenoma	6	4.54	1.66	2.74	1.04
JUNB	6	5.26	1.92	2.74	1.04
Dipeptidyl Peptidases	6	5.57	2.03	2.74	1.04
Protein Isoforms	6	5.82	2.13	2.74	1.04
Flavone	6	5.27	1.94	2.72	1.02
CCR5	6	5.15	1.90	2.71	1.01
Neurofibroma	6	5.58	2.06	2.71	1.01
Blocking Antibodies	6	5.79	2.14	2.70	1.00
NTKL	6	4.31	1.61	2.69	0.99
EWSR1	6	4.56	1.70	2.68	0.98
SCYA2	6	5.37	2.01	2.67	0.97
WT1	6	4.57	1.71	2.67	0.97
Cyproterone Acetate	6	5.15	1.93	2.67	0.97
STAT3	6	5.50	2.06	2.67	0.97
Lobular Carcinoma	6	4.13	1.56	2.65	0.95
Tyrphostin	6	5.69	2.16	2.64	0.94
CDK4	6	5.40	2.05	2.63	0.93
Euchromatin	6	4.42	1.69	2.62	0.92
Large-Cell Lymphoma	6	5.72	2.20	2.60	0.90
THPO	6	4.95	1.92	2.58	0.88
PLEK	6	4.72	1.83	2.58	0.88
Isoflavone	6	4.80	1.87	2.56	0.86
MMP3	6	5.13	2.01	2.56	0.86
CD79A	6	4.33	1.69	2.56	0.86
Poly A	6	4.85	1.90	2.55	0.85
PTGS1	6	5.82	2.28	2.55	0.85
BMP2	6	4.74	1.86	2.55	0.85
Clomiphene	6	5.03	1.98	2.54	0.84
Histone Deacetylase	6	4.98	1.97	2.53	0.83
Lysophospholipid	6	5.08	2.01	2.52	0.82
ALOPECIA AREATA	6	3.98	1.58	2.52	0.82
MT1E	6	5.22	2.07	2.52	0.82
NTF3	6	4.91	1.95	2.51	0.81
Paraganglioma	6	4.57	1.82	2.51	0.81
Diethylnitrosamine	6	5.32	2.12	2.51	0.81
Hyperprolactinemia	6	5.49	2.19	2.51	0.81
Sphingolipid	6	5.86	2.35	2.49	0.79
SP3	6	4.63	1.86	2.48	0.78
Nucleoside-Diphosphate Kinase	6	4.13	1.66	2.48	0.78
2-Acetylaminofluorene	6	5.20	2.10	2.48	0.78
Hirudin	6	5.29	2.14	2.47	0.77
Factor XIII	6	4.86	1.97	2.47	0.77
PF4	6	5.72	2.32	2.47	0.77

FIG. 27-15



NEVI	6	5.55	2.26	2.45	0.75
Lipoxygenase Inhibitors	6	4.61	1.89	2.44	0.74
TIMP2	6	4.79	1.97	2.44	0.74
CCAAT-Enhancer-Binding Proteins	6	3.97	1.63	2.43	0.73
Ursodeoxycholic Acid	6	4.97	2.04	2.43	0.73
Diphtheria Toxin	6	5.25	2.19	2.40	0.70
Nocodazole	6	5.77	2.41	2.39	0.69
NRCAM	6	4.82	2.03	2.37	0.67
Cytokine Receptors	6	5.82	2.49	2.34	0.64
Tropomyosin	6	5.09	2.18	2.33	0.63
MERTK	6	4.72	2.02	2.33	0.63
Rickets	6	5.06	2.18	2.32	0.62
ANXA5	6	5.64	2.43	2.32	0.62
Cholangiocarcinoma	6	4.50	1.94	2.32	0.62
Docosahexaenoic Acids	6	5.76	2.49	2.31	0.61
Polyvinyl Alcohol	6	5.04	2.18	2.31	0.61
Pyrrolidine	6	5.58	2.42	2.31	0.61
ADENOMATOUS POLYPOSIS OF THE COLON	6	4.38	1.90	2.30	0.60
Exotoxin	6	5.49	2.39	2.30	0.60
CDH17	6	4.41	1.93	2.29	0.59
PPBP	6	5.71	2.50	2.28	0.58
Membrane Glycoproteins	6	5.93	2.60	2.28	0.58
Pituitary Hormones	6	5.68	2.50	2.27	0.57
MYB	6	5.33	2.35	2.27	0.57
wnt	6	4.16	1.84	2.26	0.56
Teratocarcinoma	6	5.57	2.48	2.24	0.54
Myeloproliferative Disorder	6	5.18	2.31	2.24	0.54
cysteine protease	6	5.79	2.58	2.24	0.54
GRB2	6	4.58	2.04	2.24	0.54
Asbesto	6	5.41	2.43	2.23	0.53
Mineralocorticoid	6	5.57	2.52	2.21	0.51
Monosomy	6	4.98	2.25	2.21	0.51
myogenesis	6	5.14	2.33	2.20	0.50
ENTPD2	6	4.55	2.07	2.20	0.50
Fibrous Histiocytoma	6	4.47	2.05	2.18	0.48
Carcinoid Tumor	6	4.79	2.20	2.18	0.48
SCLC	6	4.40	2.02	2.18	0.48
RALY	6	4.22	1.95	2.17	0.47
Hyperoxia	6	5.46	2.53	2.16	0.46
TXN	6	5.74	2.66	2.16	0.46
HEREDITARY PANCREATITIS	6	5.58	2.59	2.16	0.46
Hemangiopericytoma	6	3.50	1.62	2.16	0.46
ANPEP	6	5.17	2.40	2.15	0.45
GAMMA-2 PHOSPHOLIPASE C	6	4.88	2.27	2.15	0.45
Streptavidin	6	5.39	2.53	2.13	0.43
Hyperparathyroidism	6	5.80	2.73	2.13	0.43
Trans-Activator	6	5.39	2.54	2.13	0.43
Hyperaldosteronism	6	5.40	2.54	2.12	0.42
PROS1	6	4.87	2.29	2.12	0.42
Amenorrhea	6	5.47	2.58	2.12	0.42
Butanol	6	5.51	2.61	2.11	0.41
N-Acetylneuraminic Acid	6	5.16	2.45	2.11	0.41

FIG. 27-16

Carotenoid	6	5.40	2.56	2.11	0.41
Thymidine Phosphorylase	6	3.13	1.49	2.10	0.40
Factor Xa	6	4.78	2.28	2.09	0.39
Butyric Acid	6	4.87	2.34	2.08	0.38
POLYCYSTIC KIDNEYS	6	5.04	2.42	2.08	0.38
Lymphoproliferative Disorder	6	5.38	2.60	2.07	0.37
Glycosphingolipid	6	5.05	2.46	2.06	0.36
Protein-Tyrosine-Phosphatase	6	4.99	2.43	2.05	0.35
DOMAINS	6	4.71	2.30	2.05	0.35
Bombesin	6	5.24	2.57	2.04	0.34
Leupeptin	6	5.81	2.84	2.04	0.34
Pulmonary Fibrosis	6	5.94	2.91	2.04	0.34
SUPPRESSOR OF TUMORIGENICITY 8	6	4.65	2.29	2.03	0.33
APOE	6	5.82	2.87	2.03	0.33
NASOPHARYNGEAL CANCER	6	4.80	2.37	2.02	0.32
Glycogen Synthase	6	4.68	2.31	2.02	0.32
Antithrombin	6	4.50	2.23	2.02	0.32
Thrombospondin	6	4.37	2.18	2.01	0.31
Subarachnoid Hemorrhage	6	5.47	2.73	2.01	0.31
INTERLEUKIN 1-ALPHA	6	5.58	2.78	2.00	0.30
Chemotactic Factors	6	5.57	2.78	2.00	0.30
RNA POLYMERASE III TRANSCRIPT 1	6	4.30	2.15	2.00	0.30
Octreotide	6	4.98	2.51	1.99	0.29
Chondroitin	6	5.16	2.61	1.98	0.28
Trace Elements	6	5.84	2.96	1.98	0.28
Thapsigargin	6	5.93	3.01	1.97	0.27
ALPHA-L INTEGRIN	6	4.56	2.32	1.97	0.27
BCR	6	5.15	2.63	1.96	0.26
AKT1	6	4.99	2.55	1.96	0.26
GH1	6	4.70	2.41	1.95	0.25
Neuritis	6	4.38	2.25	1.95	0.25
Pentose	6	4.72	2.43	1.94	0.24
MEMBER Q HISTONE 2B FAMILY	6	4.39	2.27	1.94	0.24
Calcineurin	6	4.90	2.54	1.93	0.23
Naltrexone	6	4.39	2.27	1.93	0.23
MEMBRANE METALLOENDOPEPTIDASE	6	4.63	2.40	1.93	0.23
B7	6	4.74	2.46	1.92	0.22
Angina Pectoris	6	5.29	2.75	1.92	0.22
ENOLASE 2	6	5.89	3.07	1.92	0.22
Procollagen	6	5.55	2.92	1.90	0.20
BAG1	6	5.58	2.95	1.89	0.19
Pre-Eclampsia	6	5.55	2.93	1.89	0.19
DNM1	6	4.81	2.54	1.89	0.19
Trypsin Inhibitors	6	5.88	3.12	1.88	0.18
Delayed Hypersensitivity	6	5.36	2.85	1.88	0.18
Leukotriene B4	6	5.89	3.15	1.87	0.17
Viral Antigens	6	5.19	2.78	1.87	0.17
Alcian Blue	6	4.84	2.60	1.86	0.16
EDN1	6	5.83	3.13	1.86	0.16
ALPHA-M INTEGRIN	6	5.64	3.04	1.86	0.16
Mutagen	6	5.33	2.87	1.86	0.16
Putrescine	6	5.84	3.15	1.86	0.16

FIG. 27-17

Acute-Phase Proteins	6	4.92	2.65	1.85	0.15
increases	6	5.40	2.93	1.84	0.14
PLAT	6	5.40	2.93	1.84	0.14
Corn Oil	6	5.58	3.03	1.84	0.14
Xylose	6	4.61	2.51	1.84	0.14
Amiloride	6	5.82	3.18	1.83	0.13
Monosaccharide	6	4.50	2.46	1.83	0.13
Protein Subunits	6	4.74	2.60	1.82	0.12
Disaccharide	6	4.97	2.73	1.82	0.12
Insulinoma	6	4.82	2.66	1.81	0.11
Aromatic Hydrocarbons	6	4.95	2.73	1.81	0.11
Stearic Acids	6	4.67	2.59	1.80	0.10
Dietary Fats	6	4.82	2.68	1.80	0.10
Hyperinsulinemia	6	4.97	2.77	1.80	0.10
Sphingomyelin	6	5.73	3.19	1.80	0.10
Ranitidine	6	5.08	2.83	1.79	0.09
Ethanolamine	6	5.07	2.84	1.79	0.09
TNFRSF6	6	4.74	2.66	1.78	0.08
Arteriosclerosis	6	4.98	2.81	1.77	0.07
Hematoxylin	6	5.63	3.19	1.77	0.07
Graves' Disease	6	4.76	2.73	1.75	0.05
Glucosamine	6	5.50	3.15	1.74	0.04
Deferoxamine	6	4.78	2.74	1.74	0.04
CP	6	5.97	3.43	1.74	0.04
Lymphokine	6	5.55	3.19	1.74	0.04
Puromycin	6	5.32	3.07	1.73	0.03
Mitochondrial DNA	6	5.76	3.32	1.73	0.03
Isomerase	6	5.07	2.93	1.73	0.03
Protoporphyrin	6	4.56	2.64	1.73	0.03
Peptide Fragments	6	5.34	3.10	1.72	0.02
Palmitate	6	5.72	3.32	1.72	0.02
Cytoskeletal Proteins	6	5.98	3.48	1.72	0.02
Kidney Disease	6	4.70	2.74	1.72	0.02
Lipid Peroxides	6	4.98	2.90	1.72	0.02
Lysophosphatidylcholine	6	4.54	2.65	1.71	0.01
MEMBER 1 SUBFAMILY B ATP-BINDING CASSETTE	6	4.40	2.60	1.70	0.00
Uridine Triphosphate	6	5.12	3.03	1.69	-0.01
Cholinesterase	6	5.57	3.30	1.69	-0.01
BONE GAMMA-CARBOXYGLUTAMIC ACID PROTEIN	6	4.79	2.85	1.68	-0.02
Ethidium	6	5.71	3.41	1.68	-0.02
Oleic Acid	6	5.82	3.47	1.68	-0.02
IGHG2	6	4.29	2.56	1.67	-0.03
Pulmonary Hypertension	6	5.50	3.30	1.67	-0.03
Venom	6	5.51	3.30	1.67	-0.03
RESPIRATORY DISTRESS SYNDROME	6	5.81	3.49	1.66	-0.04
beta-Endorphin	6	4.98	3.00	1.66	-0.04
Coenzyme A	6	5.65	3.41	1.66	-0.04
Uremia	6	5.44	3.29	1.66	-0.04
Ribonucleoprotein	6	4.99	3.03	1.65	-0.05
THM	6	4.57	2.81	1.63	-0.07
Indole	6	5.31	3.27	1.63	-0.07
Hepatitis C	6	5.30	3.29	1.61	-0.09

FIG. 27-18

Colitis	6	5.81	3.61	1.61	-0.09
Myelodysplastic Syndromes	6	4.32	2.69	1.61	-0.09
Calcium Phosphates	6	4.95	3.10	1.60	-0.10
ACE	6	5.82	3.66	1.59	-0.11
SERPINB4	6	5.97	3.77	1.58	-0.12
Cytochrome-c Oxidase	6	4.89	3.09	1.58	-0.12
Nickel	6	5.83	3.69	1.58	-0.12
Trichloroacetic Acid	6	4.81	3.06	1.57	-0.13
beta Carotene	6	4.43	2.81	1.57	-0.13
GAS	6	5.00	3.20	1.56	-0.14
G6PD	6	5.82	3.74	1.56	-0.14
Heavy Metals	6	4.73	3.04	1.55	-0.15
Ammonium Chloride	6	4.53	2.92	1.55	-0.15
GSR	6	4.49	2.93	1.53	-0.17
Leukotriene	6	5.38	3.51	1.53	-0.17
Suramin	6	4.40	2.88	1.53	-0.17
Hemagglutinin	6	4.64	3.03	1.53	-0.17
Encephalomyelitis	6	4.56	2.98	1.53	-0.17
ASTHMA	6	4.92	3.22	1.53	-0.17
Zymosan	6	5.09	3.34	1.52	-0.18
Phosphatidylserine	6	5.98	3.93	1.52	-0.18
Allopurinol	6	4.52	2.99	1.51	-0.19
C3	6	4.12	2.73	1.51	-0.19
Freund's Adjuvant	6	4.21	2.80	1.51	-0.19
Hematuria	6	4.81	3.19	1.51	-0.19
Diuretic	6	5.39	3.58	1.51	-0.19
Opioid Receptors	6	3.81	2.55	1.49	-0.21
Hydroxyapatite	6	5.51	3.70	1.49	-0.21
PALMOPLANTAR KERATODERMA	6	5.43	3.67	1.48	-0.22
ENDOMETRIOSIS	6	3.66	2.48	1.48	-0.22
Corticosterone	6	5.98	4.07	1.47	-0.23
P-Glycoprotein	6	4.76	3.24	1.47	-0.23
Encephalitis	6	4.98	3.39	1.47	-0.23
Opportunistic Infection	6	4.53	3.09	1.47	-0.23
Uridine	6	5.40	3.71	1.45	-0.25
Blindness	6	5.24	3.61	1.45	-0.25
ESOPHAGEAL CANCER	6	3.55	2.47	1.44	-0.26
Propionate	6	5.62	3.93	1.43	-0.27
OSTEOARTHRITIS	6	5.33	3.72	1.43	-0.27
NPPA	6	4.64	3.27	1.42	-0.28
Linoleic Acid	6	4.81	3.40	1.41	-0.29
Gelatin	6	5.75	4.07	1.41	-0.29
Anthracycline	6	3.98	2.82	1.41	-0.29
NDUFB3	6	5.03	3.57	1.41	-0.29
RHO6	6	3.67	2.61	1.40	-0.30
TH	6	4.65	3.32	1.40	-0.30
CCK	6	4.78	3.43	1.39	-0.31
Dipeptide	6	5.32	3.82	1.39	-0.31
INSR	6	4.49	3.23	1.39	-0.31
Hydroxylase	6	5.20	3.74	1.39	-0.31
Asparagine	6	5.73	4.13	1.39	-0.31
Demyelinating	6	4.39	3.17	1.39	-0.31

FIG. 27-19

Sodium Azide	6	4.32	3.12	1.38	-0.32
Hydrolase	6	5.74	4.16	1.38	-0.32
Hypothermia	6	5.46	3.97	1.38	-0.32
Citric Acid	6	4.22	3.08	1.37	-0.33
Stomatitis	6	4.91	3.58	1.37	-0.33
Guanidine	6	5.07	3.71	1.37	-0.33
alpha-Tocopherol	6	4.74	3.48	1.36	-0.34
Myocardial Ischemia	6	4.37	3.25	1.35	-0.35
Hepatitis B	6	5.52	4.11	1.34	-0.36
ki-67	6	3.00	2.24	1.34	-0.36
Acetonitrile	6	5.13	3.85	1.33	-0.37
Interferon-alpha	6	4.51	3.38	1.33	-0.37
NPY	6	4.16	3.12	1.33	-0.37
Influenza	6	5.54	4.17	1.33	-0.37
Barium	6	5.22	3.93	1.33	-0.37
Tetracycline	6	5.82	4.41	1.32	-0.38
Pyridine	6	5.05	3.83	1.32	-0.38
Osteoporosis	6	4.81	3.66	1.31	-0.39
Chloroquine	6	5.37	4.11	1.31	-0.39
Ammonium Sulfate	6	5.72	4.38	1.31	-0.39
Cholera Toxin	6	4.85	3.72	1.30	-0.40
Interleukin-8	6	3.99	3.07	1.30	-0.40
Gonadotropin	6	4.57	3.53	1.29	-0.41
Bleomycin	6	4.62	3.57	1.29	-0.41
DEAE-Cellulose	6	5.13	3.97	1.29	-0.41
Alkylating Agent	6	5.00	3.87	1.29	-0.41
TESTICULAR TUMORS	6	3.65	2.83	1.29	-0.41
NONINSULIN-DEPENDENT DIABETES MELLITUS	6	4.37	3.39	1.29	-0.41
Acidosis	6	5.83	4.52	1.29	-0.41
Cadmium	6	5.13	4.02	1.28	-0.42
Cyclic GMP	6	4.22	3.32	1.27	-0.43
Polyethylene Glycols	6	5.55	4.37	1.27	-0.43
Blood Glucose	6	5.57	4.39	1.27	-0.43
Aldosterone	6	4.93	3.91	1.26	-0.44
Formaldehyde	6	5.23	4.15	1.26	-0.44
Hypoglycemia	6	4.93	3.94	1.25	-0.45
Chemokine	6	3.83	3.07	1.25	-0.45
Ascorbic Acid	6	5.54	4.46	1.24	-0.46
Pyruvate	6	5.75	4.66	1.23	-0.47
MS	6	5.15	4.18	1.23	-0.47
Vasculitis	6	4.98	4.06	1.23	-0.47
Melatonin	6	3.97	3.27	1.21	-0.49
Cholestasis	6	4.14	3.43	1.21	-0.49
Erythromycin	6	4.65	3.87	1.20	-0.50
Coagulase	6	4.70	3.91	1.20	-0.50
Cellulose	6	5.96	4.96	1.20	-0.50
Epilepsy	6	5.70	4.78	1.19	-0.51
Cholera	6	3.54	3.00	1.18	-0.52
Glutamic Acid	6	5.92	5.10	1.16	-0.54
Sodium Fluoride	6	3.29	2.86	1.15	-0.55
Nitrate	6	5.37	4.70	1.14	-0.56
Manganese	6	4.48	3.93	1.14	-0.56

FIG. 27-20

ACHE	6	4.54	4.05	1.12	-0.58
Hypercalcemia	6	3.50	3.16	1.11	-0.59
Ulcer	6	4.85	4.42	1.10	-0.60
Phenol	6	4.90	4.49	1.09	-0.61
Acid Phosphatase	6	4.96	4.58	1.08	-0.62
Ganglioside	6	3.96	3.65	1.08	-0.62
Cytosine	6	4.68	4.33	1.08	-0.62
Hydroxyproline	6	3.57	3.34	1.07	-0.63
Colchicine	6	4.82	4.56	1.06	-0.64
MMP9	6	2.82	2.69	1.05	-0.65
Vasopressin	6	4.54	4.32	1.05	-0.65
Theophylline	6	4.58	4.45	1.03	-0.67
Verapamil	6	4.82	4.72	1.02	-0.68
Diarrhea	6	5.40	5.50	0.98	-0.72
PTGS2	6	2.93	3.02	0.97	-0.73
Morphine	6	4.24	4.42	0.96	-0.74
PHEOCHROMOCYTOMA	6	3.58	3.76	0.95	-0.75
Carcinogen	6	3.82	4.02	0.95	-0.75
Divalent Cations	6	3.98	4.24	0.94	-0.76
Guanine	6	4.58	4.88	0.94	-0.76
Fatigue	6	4.38	4.76	0.92	-0.78
Rupture	6	4.57	5.04	0.91	-0.79
Analgesic	6	4.43	4.89	0.91	-0.79
Norepinephrine	6	4.75	5.27	0.90	-0.80
Epinephrine	6	4.57	5.08	0.90	-0.80
Cisplatin	6	3.82	4.31	0.89	-0.81
GCG	6	3.91	4.49	0.87	-0.83
PLG	6	2.83	3.37	0.84	-0.86
Shock	6	5.99	7.21	0.83	-0.87
Granuloma	6	3.55	4.56	0.78	-0.92
Cation	6	4.58	6.59	0.70	-1.00
TDGF1	5	4.76	1.25	3.80	1.40
PTN	5	4.80	1.28	3.75	1.35
CYR61	5	4.66	1.25	3.74	1.34
INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 7	5	4.30	1.16	3.71	1.31
FOLH1	5	4.74	1.28	3.71	1.31
SCYB10	5	4.62	1.26	3.67	1.27
AKT2	5	4.32	1.22	3.54	1.14
FGF3	5	4.65	1.34	3.46	1.06
ITGA6	5	4.23	1.23	3.45	1.05
MET PROTOONCOGENE	5	4.59	1.34	3.44	1.04
CSK	5	4.19	1.24	3.38	0.98
NRAS	5	4.29	1.27	3.37	0.97
TSC2	5	4.40	1.31	3.36	0.96
EPHRIN RECEPTOR EphA2	5	4.20	1.26	3.34	0.94
IGFBP6	5	4.20	1.27	3.30	0.90
FGFR3	5	4.82	1.48	3.26	0.86
IL8RA	5	4.30	1.33	3.22	0.82
Prostatic Disease	5	4.46	1.39	3.22	0.82
SSTR1	5	4.37	1.36	3.20	0.80
PEUTZ-JEGHERS SYNDROME	5	4.40	1.38	3.19	0.79
Oncogene Proteins	5	4.04	1.28	3.16	0.76

FIG. 27-21

Hippel-Lindau Disease	5	4.81	1.53	3.14	0.74
GSTM1	5	4.78	1.53	3.12	0.72
MEMBRANE	5	4.62	1.49	3.11	0.71
Serous Cystadenocarcinoma	5	4.36	1.41	3.09	0.69
PTGER1	5	4.56	1.48	3.07	0.67
PTGER2	5	4.56	1.49	3.07	0.67
Endometrioid Carcinoma	5	3.98	1.30	3.06	0.66
Cancer Vaccines	5	3.99	1.33	3.00	0.60
Villous Adenoma	5	4.40	1.47	2.99	0.59
Interleukin-18	5	4.12	1.38	2.98	0.58
IGF2R	5	4.38	1.48	2.96	0.56
TNS	5	4.13	1.40	2.94	0.54
TRANSCRIPTION FACTOR 2	5	4.04	1.38	2.93	0.53
MYELOID CELL LEUKEMIA 1	5	4.19	1.45	2.90	0.50
src-Family Kinases	5	4.77	1.66	2.88	0.48
SYK	5	4.95	1.73	2.87	0.47
MACS	5	4.54	1.58	2.87	0.47
Thyroid Nodule	5	4.74	1.66	2.87	0.47
ICAM2	5	4.33	1.51	2.86	0.46
Immunoconjugate	5	4.40	1.54	2.86	0.46
Mantle-Cell Lymphoma	5	4.30	1.51	2.85	0.45
MITOGEN-ACTIVATED KINASE KINASE 1	5	4.46	1.56	2.85	0.45
Prolactin Receptors	5	4.16	1.46	2.85	0.45
Adenomatous Polyps	5	4.90	1.72	2.84	0.44
GSK3B	5	4.13	1.45	2.84	0.44
VIL2	5	4.38	1.54	2.84	0.44
Bowen's Disease	5	4.40	1.56	2.82	0.42
UTERINE LEIOMYOMA	5	4.97	1.76	2.82	0.42
Endometrial Hyperplasia	5	4.58	1.64	2.80	0.40
FRZB	5	3.98	1.43	2.79	0.39
Embryonal Rhabdomyosarcoma	5	4.12	1.48	2.79	0.39
CXCR4	5	4.91	1.77	2.78	0.38
Prostatic Hyperplasia	5	4.05	1.46	2.77	0.37
Serine kinase	5	4.32	1.58	2.72	0.32
ALPHA-1 LAMININ	5	4.33	1.60	2.72	0.32
MUC2	5	3.94	1.45	2.71	0.31
ATF1	5	4.14	1.53	2.70	0.30
MMP13	5	4.16	1.56	2.67	0.27
H19	5	3.96	1.48	2.67	0.27
Soybean Proteins	5	4.21	1.58	2.67	0.27
NPY6R	5	3.78	1.42	2.66	0.26
TYK2	5	4.06	1.54	2.63	0.23
Gastric Mucin	5	4.06	1.54	2.63	0.23
RAC1	5	4.91	1.87	2.62	0.22
Glucagonoma	5	4.05	1.55	2.62	0.22
DNA DAMAGE-INDUCIBLE TRANSCRIPT 3	5	4.37	1.67	2.61	0.21
IMP Dehydrogenase	5	4.03	1.54	2.61	0.21
Relaxin	5	4.79	1.84	2.60	0.20
Monocrotaline	5	4.32	1.66	2.60	0.20
FOXN1	5	4.16	1.60	2.60	0.20
Proliferative Vitreoretinopathy	5	4.35	1.68	2.59	0.19
VTNR	5	4.41	1.71	2.58	0.18

FIG. 27-22

PI31	5	4.78	1.85	2.58	0.18
B-CELL TRANSLOCATION GENE 2	5	4.97	1.94	2.56	0.16
Gastrointestinal Hormones	5	4.22	1.65	2.56	0.16
Keratosis	5	4.76	1.87	2.55	0.15
Tissue Kallikreins	5	4.13	1.62	2.54	0.14
KRT19	5	3.71	1.46	2.54	0.14
LOX	5	4.16	1.64	2.53	0.13
IL18	5	4.41	1.75	2.53	0.13
Levonorgestrel	5	4.31	1.71	2.52	0.12
Swainsonine	5	4.15	1.65	2.51	0.11
gamma-Linolenic Acid	5	4.57	1.82	2.51	0.11
NPM1	5	4.06	1.62	2.51	0.11
Mucoepidermoid Carcinoma	5	3.88	1.55	2.50	0.10
KRT18	5	4.50	1.81	2.49	0.09
HYDM	5	4.52	1.82	2.48	0.08
Craniopharyngioma	5	4.35	1.75	2.48	0.08
STHM	5	4.48	1.81	2.47	0.07
SQSTM1	5	4.32	1.75	2.47	0.07
Curcumin	5	4.99	2.03	2.46	0.06
STAT5A	5	4.40	1.80	2.45	0.05
NTRK1	5	5.00	2.04	2.45	0.05
HMOX1	5	4.75	1.96	2.42	0.02
Pulmonary Sarcoidosis	5	4.44	1.85	2.41	0.01
IL9	5	3.90	1.62	2.41	0.01
IRF1	5	3.64	1.52	2.40	0.00
CD63	5	4.23	1.76	2.40	0.00
BMP4	5	3.96	1.65	2.40	0.00
Connexin	5	4.29	1.80	2.39	-0.01
Activin	5	4.80	2.02	2.38	-0.02
MUC5AC	5	3.23	1.36	2.38	-0.02
EEF2	5	4.20	1.77	2.37	-0.03
DNA Topoisomerases	5	4.65	1.96	2.37	-0.03
Sunburn	5	3.74	1.58	2.37	-0.03
X-LINKED PREMATURE OVARIAN FAILURE	5	3.57	1.51	2.37	-0.03
NTF5	5	3.64	1.54	2.37	-0.03
NP	5	4.74	2.01	2.36	-0.04
IL11	5	4.37	1.86	2.35	-0.05
KALLIKREIN 2	5	3.67	1.56	2.35	-0.05
EthylNitrosourea	5	4.58	1.95	2.35	-0.05
F5	5	4.28	1.82	2.35	-0.05
Chromogranin	5	4.64	1.98	2.35	-0.05
Cystadenocarcinoma	5	3.71	1.58	2.35	-0.05
RBL2	5	4.55	1.94	2.34	-0.06
Cryptorchidism	5	4.79	2.05	2.34	-0.06
Recombinant Interferon-gamma	5	4.96	2.12	2.34	-0.06
ALPHA-4 INTEGRIN	5	3.89	1.66	2.34	-0.06
Lutein	5	4.33	1.86	2.33	-0.07
SONIC HEDGEHOG	5	3.71	1.59	2.33	-0.07
NP25	5	3.80	1.63	2.33	-0.07
Serpin	5	4.65	2.00	2.32	-0.08
Sulindac	5	4.78	2.06	2.32	-0.08
CD58	5	3.98	1.72	2.31	-0.09

FIG. 27-23



Ganglioneuroma	5	3.73	1.62	2.30	-0.10
Reticulin	5	4.52	1.97	2.30	-0.10
Deoxyglucose	5	4.54	1.97	2.30	-0.10
SPF45	5	3.64	1.59	2.30	-0.10
Adenosquamous Carcinoma	5	3.54	1.54	2.29	-0.11
Atrophic Gastritis	5	4.20	1.84	2.29	-0.11
Norgestrel	5	3.32	1.45	2.28	-0.12
VHL	5	3.82	1.68	2.28	-0.12
TGM2	5	4.57	2.01	2.28	-0.12
CSN2	5	4.63	2.03	2.28	-0.12
V-SRC AVIAN SARCOMA VIRAL ONCOGENE	5	3.57	1.57	2.27	-0.13
Vinca Alkaloids	5	4.20	1.85	2.27	-0.13
RAB1B	5	4.39	1.94	2.27	-0.13
Sarcoma 180	5	4.52	1.99	2.27	-0.13
LIPC	5	4.11	1.82	2.26	-0.14
LOW-GRADE B-CELL MALIGNANCY	5	4.61	2.04	2.26	-0.14
IDIOPATHIC PULMONARY FIBROSIS	5	4.37	1.94	2.26	-0.14
DSP	5	3.74	1.66	2.25	-0.15
Transferrin Receptors	5	4.54	2.02	2.25	-0.15
CD36	5	4.79	2.13	2.24	-0.16
CTRL	5	4.31	1.92	2.24	-0.16
GZMB	5	4.07	1.82	2.24	-0.16
Osteitis	5	4.21	1.89	2.22	-0.18
Sesquiterpene	5	4.20	1.89	2.22	-0.18
PTK9	5	4.72	2.13	2.22	-0.18
SCYA4	5	3.95	1.79	2.21	-0.19
TUBEROUS SCLEROSIS	5	4.57	2.07	2.21	-0.19
Anti-Idiotypic Antibodies	5	4.58	2.08	2.20	-0.20
CDKN2A	5	3.55	1.61	2.20	-0.20
MYOG	5	3.78	1.72	2.19	-0.21
SLC3A2	5	3.65	1.67	2.19	-0.21
G8	5	3.40	1.56	2.18	-0.22
PTAFR	5	3.39	1.56	2.18	-0.22
Raloxifene	5	3.23	1.48	2.18	-0.22
Transaldolase	5	3.99	1.83	2.18	-0.22
BCL2	5	4.82	2.23	2.17	-0.23
Benzamidine	5	3.88	1.79	2.16	-0.24
Safflower Oil	5	3.89	1.80	2.16	-0.24
CXC Chemokines	5	3.96	1.84	2.15	-0.25
SCYA11	5	3.71	1.72	2.15	-0.25
Flutamide	5	4.09	1.90	2.15	-0.25
Hyperandrogenism	5	3.37	1.57	2.15	-0.25
ADPRT	5	4.06	1.89	2.14	-0.26
Gossypol	5	4.13	1.93	2.14	-0.26
Tetradecanoylphorbol Acetate	5	4.10	1.93	2.12	-0.28
Fibrillar Collagens	5	3.73	1.78	2.10	-0.30
Flurbiprofen	5	4.50	2.15	2.09	-0.31
Deoxyuridine	5	4.56	2.19	2.08	-0.32
Hyperlipoproteinemia	5	4.14	1.99	2.08	-0.32
Hirsutism	5	4.37	2.10	2.08	-0.32
Glucuronidase	5	4.62	2.22	2.08	-0.32
Anisomycin	5	4.27	2.06	2.07	-0.33

FIG. 27-24

HDC	5	3.96	1.91	2.07	-0.33
THR	5	4.09	1.97	2.07	-0.33
Macular Degeneration	5	4.14	2.00	2.07	-0.33
CNTF	5	4.04	1.95	2.07	-0.33
Magnesium Deficiency	5	4.16	2.01	2.06	-0.34
LYMPHOTOXIN-ALPHA	5	3.40	1.65	2.06	-0.34
B2M	5	4.10	1.99	2.06	-0.34
Deoxyadenosine	5	3.95	1.93	2.05	-0.35
Norethindrone	5	3.32	1.62	2.05	-0.35
SSX1	5	3.55	1.74	2.04	-0.36
Dermatan Sulfate	5	4.34	2.13	2.04	-0.36
NDUFA2	5	4.13	2.03	2.03	-0.37
Estradiol Receptors	5	3.23	1.59	2.03	-0.37
SDC2	5	4.40	2.18	2.02	-0.38
NOS3	5	4.31	2.14	2.01	-0.39
IL1RN	5	4.21	2.10	2.00	-0.40
PHB	5	3.34	1.67	2.00	-0.40
CTSG	5	4.17	2.09	2.00	-0.40
BMP	5	4.13	2.07	2.00	-0.40
Sialoglycoprotein	5	3.70	1.87	1.98	-0.42
Bacterial Toxins	5	4.06	2.05	1.98	-0.42
GCK	5	3.98	2.01	1.98	-0.42
CD68	5	4.75	2.40	1.98	-0.42
Galactosyltransferase	5	4.40	2.23	1.97	-0.43
Germinoma	5	2.91	1.48	1.97	-0.43
GLUCOSE-6-PHOSPHATE ISOMERASE	5	3.85	1.96	1.97	-0.43
Unstable Angina	5	4.37	2.22	1.97	-0.43
Phosphofructokinase	5	4.81	2.45	1.97	-0.43
Pulmonary Surfactants	5	4.29	2.19	1.96	-0.44
F8	5	3.98	2.04	1.95	-0.45
Goiter	5	4.99	2.58	1.94	-0.46
Interleukin-2 Receptors	5	4.31	2.23	1.93	-0.47
HLA-D HISTOCOMPATIBILITY TYPE	5	4.33	2.24	1.93	-0.47
Transducin	5	3.37	1.75	1.93	-0.47
Factor X	5	4.08	2.11	1.93	-0.47
HOMOLOG-LIKE DROSOPHILA SINGED	5	4.72	2.45	1.92	-0.48
Ormeprazole	5	4.85	2.52	1.92	-0.48
UP	5	3.81	1.99	1.91	-0.49
3-@HYDROXY-3-METHYLGLUTARYL-CoA REDUCTASE	5	4.77	2.50	1.91	-0.49
Polyurethane	5	4.30	2.25	1.91	-0.49
Piroxicam	5	4.53	2.38	1.90	-0.50
TYR	5	4.93	2.60	1.90	-0.50
Glycosylphosphatidylinositol	5	4.37	2.31	1.89	-0.51
Dimethylnitrosamine	5	3.92	2.07	1.89	-0.51
ABDOMINAL AORTIC ANEURYSM	5	4.13	2.19	1.89	-0.51
Ethyl Methanesulfonate	5	3.92	2.08	1.89	-0.51
Silver Nitrate	5	4.20	2.23	1.88	-0.52
Interferon-beta	5	4.80	2.56	1.88	-0.52
Picoline	5	4.23	2.26	1.87	-0.53
Factor VII	5	4.13	2.20	1.87	-0.53
Lichen Planus	5	3.93	2.11	1.86	-0.54
TGM1	5	3.54	1.91	1.85	-0.55

FIG. 27-25

HLA-DR Antigens	5	3.88	2.10	1.85	-0.55
PPP1R13B	5	3.95	2.13	1.85	-0.55
PTEN	5	3.00	1.62	1.85	-0.55
Ganciclovir	5	4.50	2.44	1.85	-0.55
Losartan	5	4.33	2.35	1.85	-0.55
Oligodeoxyribonucleotide	5	4.60	2.50	1.84	-0.56
CLU	5	3.67	1.99	1.84	-0.56
Carcinosarcoma	5	3.96	2.15	1.84	-0.56
Arsenic	5	4.97	2.71	1.83	-0.57
TNFRSF5	5	4.51	2.47	1.83	-0.57
PHOSPHORIBOSYLTRANSFERASE 1	5	4.65	2.55	1.83	-0.57
Arteriovenous Malformations	5	4.33	2.37	1.83	-0.57
Spironolactone	5	4.37	2.40	1.82	-0.58
Avidin	5	4.79	2.64	1.82	-0.58
Wegener's Granulomatosis	5	3.80	2.10	1.81	-0.59
ALPHA-X INTEGRIN	5	3.78	2.09	1.81	-0.59
Lipid A	5	4.48	2.48	1.81	-0.59
Buthionine Sulfoximine	5	4.53	2.51	1.81	-0.59
SP2	5	3.92	2.17	1.81	-0.59
Dopamine Agonists	5	4.45	2.47	1.80	-0.60
Titanium	5	4.65	2.58	1.80	-0.60
Hypokinesia	5	3.71	2.06	1.80	-0.60
Methacrylate	5	4.65	2.59	1.79	-0.61
SYP	5	4.40	2.47	1.78	-0.62
Polyuria	5	4.54	2.55	1.78	-0.62
CHONDROSARCOMA	5	3.99	2.24	1.78	-0.62
PROTEIN EXPRESSED IN NONMETASTATIC CELLS 1	5	2.83	1.59	1.78	-0.62
Homocysteine	5	4.96	2.80	1.77	-0.63
Minocycline	5	4.13	2.34	1.77	-0.63
Angiotensin Amide	5	4.93	2.79	1.77	-0.63
LEP	5	4.58	2.60	1.76	-0.64
Thyroiditis	5	4.82	2.73	1.76	-0.64
DEAFNESS	5	4.34	2.47	1.76	-0.64
Fatty Liver	5	4.52	2.58	1.75	-0.65
Pentoxifylline	5	4.58	2.62	1.75	-0.65
Polylysine	5	4.38	2.51	1.75	-0.65
Histocompatibility Antigens	5	4.65	2.66	1.75	-0.65
Nordihydroguaiaretic Acid	5	4.40	2.52	1.74	-0.66
Keratan Sulfate	5	3.15	1.81	1.74	-0.66
CD59	5	3.32	1.91	1.74	-0.66
Glycosuria	5	3.39	1.95	1.74	-0.66
Glyceraldehyde	5	3.54	2.04	1.73	-0.67
Aprotinin	5	4.91	2.83	1.73	-0.67
Hexosamine	5	3.81	2.20	1.73	-0.67
Thalidomide	5	3.66	2.11	1.73	-0.67
Dyspepsia	5	3.97	2.29	1.73	-0.67
RCCP2	5	2.91	1.68	1.73	-0.67
Hypogonadism	5	4.21	2.44	1.73	-0.67
Contractile Proteins	5	3.81	2.21	1.73	-0.67
Intestinal Obstruction	5	4.08	2.37	1.73	-0.67
Phosphocreatine	5	4.32	2.51	1.72	-0.68
Glucocorticoid Receptors	5	4.33	2.51	1.72	-0.68

FIG. 27-26

Acyltransferase	5	4.20	2.44	1.72	-0.68
Carbamate	5	4.80	2.80	1.71	-0.69
LDL Receptors	5	4.23	2.47	1.71	-0.69
Schistosomiasis	5	4.57	2.69	1.70	-0.70
ALZHEIMER DISEASE	5	4.23	2.49	1.70	-0.70
OSTEOGENIC SARCOMA	5	3.55	2.09	1.70	-0.70
Calcitriol	5	3.66	2.16	1.69	-0.71
Thallium	5	3.73	2.21	1.69	-0.71
BETA-2 INTEGRIN	5	4.91	2.90	1.69	-0.71
Chronic Bronchitis	5	4.58	2.71	1.69	-0.71
Ribonucleoside	5	3.49	2.07	1.68	-0.72
Evans Blue	5	4.40	2.62	1.68	-0.72
Ewing's Sarcoma	5	3.48	2.08	1.68	-0.72
Cysteamine	5	4.03	2.42	1.67	-0.73
Milk Proteins	5	4.15	2.49	1.67	-0.73
Synovitis	5	4.38	2.63	1.67	-0.73
Phosphoserine	5	4.01	2.41	1.67	-0.73
Sulfoxide	5	4.44	2.67	1.66	-0.74
S-Adenosylmethionine	5	4.19	2.52	1.66	-0.74
TYMS	5	3.75	2.26	1.66	-0.74
PRIMARY BILIARY CIRRHOSIS	5	4.66	2.81	1.66	-0.74
Steel	5	4.22	2.56	1.65	-0.75
Toluidine	5	4.55	2.76	1.65	-0.75
DIA4	5	3.84	2.33	1.65	-0.75
Rotenone	5	4.54	2.76	1.64	-0.76
HLA-A	5	3.98	2.43	1.64	-0.76
Leukotriene C4	5	4.50	2.74	1.64	-0.76
PROTEASE INHIBITOR 1	5	4.72	2.89	1.63	-0.77
Sulfatase	5	3.31	2.04	1.62	-0.78
TM4SF1	5	4.40	2.71	1.62	-0.78
hemangioma	5	3.55	2.19	1.62	-0.78
SHBG	5	3.79	2.34	1.62	-0.78
Chloride Channels	5	4.23	2.62	1.62	-0.78
Silicon	5	4.36	2.70	1.62	-0.78
Lymphocytosis	5	4.09	2.53	1.61	-0.79
Cyclooxygenase Inhibitors	5	4.83	2.99	1.61	-0.79
Convalescence	5	4.08	2.53	1.61	-0.79
Ethylenediamine	5	4.23	2.62	1.61	-0.79
Propylthiouracil	5	3.81	2.37	1.61	-0.79
CD9	5	4.82	3.01	1.60	-0.80
ion transport	5	4.20	2.63	1.60	-0.80
ZYX	5	4.20	2.63	1.60	-0.80
HEMOLYTIC-UREMIC SYNDROME	5	3.56	2.23	1.60	-0.80
Protamine	5	4.96	3.12	1.59	-0.81
Demethylation	5	4.81	3.02	1.59	-0.81
Glycolipid	5	4.78	3.00	1.59	-0.81
Calcimycin	5	4.64	2.92	1.59	-0.81
Periodontitis	5	4.23	2.66	1.59	-0.81
NADPH Oxidase	5	4.15	2.62	1.59	-0.81
Retinal Degeneration	5	3.80	2.40	1.59	-0.81
Tuberculin	5	4.08	2.58	1.58	-0.82
DILATED CARDIOMYOPATHY 1A	5	4.72	3.00	1.57	-0.83

FIG. 27-27

Glucose-6-Phosphate	5	3.99	2.54	1.57	-0.83
Cytomegalovirus Infection	5	4.02	2.58	1.56	-0.84
Ketone Bodies	5	3.71	2.38	1.56	-0.84
Prostaglandin D2	5	3.91	2.52	1.55	-0.85
Periodic Acid	5	3.50	2.25	1.55	-0.85
Reperfusion Injury	5	4.32	2.79	1.55	-0.85
NBP	5	3.59	2.32	1.55	-0.85
Membrane Lipids	5	4.65	3.04	1.53	-0.87
Endothelin	5	4.99	3.28	1.52	-0.88
NCAM1	5	4.16	2.73	1.52	-0.88
Pyridoxine	5	4.03	2.65	1.52	-0.88
Ketoconazole	5	4.79	3.16	1.51	-0.89
Portal Hypertension	5	4.13	2.73	1.51	-0.89
Perchloric Acid	5	3.81	2.53	1.51	-0.89
DHFR	5	4.34	2.88	1.51	-0.89
Alginate	5	4.01	2.66	1.51	-0.89
Opioid Peptides	5	3.99	2.65	1.51	-0.89
Succinate Dehydrogenase	5	4.39	2.92	1.50	-0.90
Hemangioma	5	3.65	2.43	1.50	-0.90
NEUROPATHY	5	4.48	2.98	1.50	-0.90
PLA2G1B	5	4.46	2.97	1.50	-0.90
CHOLESTASIS	5	4.41	2.94	1.50	-0.90
Cytochalasin B	5	4.92	3.29	1.50	-0.90
MMP1	5	3.57	2.39	1.50	-0.90
HLA Antigens	5	3.74	2.50	1.50	-0.90
Fumarate	5	3.98	2.66	1.50	-0.90
Hemostatic	5	4.57	3.06	1.49	-0.91
Thromboxane B2	5	4.96	3.34	1.49	-0.91
Melanin	5	4.81	3.24	1.48	-0.92
Gelatinase	5	3.40	2.30	1.48	-0.92
Carbonic Anhydrases	5	4.33	2.94	1.47	-0.93
Methylcellulose	5	4.09	2.79	1.46	-0.94
Cerebellar Ataxia	5	3.91	2.67	1.46	-0.94
Capsid	5	4.22	2.89	1.46	-0.94
Papain	5	4.79	3.28	1.46	-0.94
Inosine	5	4.23	2.90	1.46	-0.94
C7	5	4.05	2.79	1.45	-0.95
Nuclear RNA	5	3.53	2.44	1.45	-0.95
Ribose	5	4.30	2.97	1.45	-0.95
HP	5	4.15	2.87	1.45	-0.95
Tyramine	5	3.81	2.64	1.45	-0.95
Estriol	5	3.16	2.19	1.44	-0.96
Antinuclear Antibodies	5	4.32	2.99	1.44	-0.96
Rhodamine	5	3.97	2.75	1.44	-0.96
Pronase	5	4.96	3.45	1.44	-0.96
Iodoacetamide	5	4.13	2.87	1.44	-0.96
Fura-2	5	4.55	3.17	1.43	-0.97
Hapten	5	4.23	2.95	1.43	-0.97
Contact Dermatitis	5	3.78	2.65	1.42	-0.98
Hemocyanin	5	3.98	2.80	1.42	-0.98
Thermolysin	5	3.14	2.22	1.42	-0.98
Glycoside	5	3.73	2.63	1.42	-0.98

FIG. 27-28

MYASTHENIA GRAVIS	5	3.98	2.82	1.41	-0.99
Pulmonary Embolism	5	3.99	2.83	1.41	-0.99
Dietary Proteins	5	3.81	2.72	1.40	-1.00
Acridine Orange	5	4.10	2.92	1.40	-1.00
Oligomycin	5	3.31	2.36	1.40	-1.00
Viral Proteins	5	3.92	2.80	1.40	-1.00
Thromboxane	5	4.99	3.57	1.40	-1.00
Endotoxemia	5	3.73	2.68	1.39	-1.01
Pruritus	5	4.47	3.21	1.39	-1.01
Contracture	5	4.40	3.16	1.39	-1.01
Rhinitis	5	4.15	2.99	1.39	-1.01
Double-Stranded RNA	5	3.14	2.26	1.39	-1.01
Hemolytic Anemia	5	4.14	2.99	1.39	-1.01
Foreign Bodies	5	4.57	3.29	1.39	-1.01
Macrolide	5	3.80	2.74	1.39	-1.01
Oligopeptide	5	4.40	3.18	1.38	-1.02
Captopril	5	4.55	3.29	1.38	-1.02
Peptidoglycan	5	3.32	2.40	1.38	-1.02
SELP	5	3.58	2.59	1.38	-1.02
Chromium	5	4.50	3.26	1.38	-1.02
Methylene Blue	5	4.90	3.56	1.37	-1.03
Flavoprotein	5	3.49	2.54	1.37	-1.03
Carboxypeptidase	5	3.96	2.89	1.37	-1.03
Sodium Bicarbonate	5	3.91	2.87	1.36	-1.04
Burns	5	4.94	3.63	1.36	-1.04
SCT	5	3.63	2.68	1.36	-1.04
Carbon Tetrachloride	5	4.07	3.00	1.36	-1.04
CEREBROVASCULAR ACCIDENT	5	4.23	3.13	1.35	-1.05
Viral DNA	5	4.09	3.03	1.35	-1.05
Bradycardia	5	4.92	3.67	1.34	-1.06
Endopeptidase	5	4.13	3.10	1.33	-1.07
Hexose	5	4.51	3.38	1.33	-1.07
Septic Shock	5	4.51	3.38	1.33	-1.07
CTSB	5	3.41	2.57	1.33	-1.07
Polystyrene	5	4.49	3.39	1.33	-1.07
Muscular Dystrophies	5	4.48	3.41	1.32	-1.08
Globin	5	3.78	2.87	1.31	-1.09
Aluminum	5	4.72	3.59	1.31	-1.09
Monensin	5	4.50	3.45	1.31	-1.09
Hepatomegaly	5	4.47	3.47	1.29	-1.11
Melphalan	5	3.41	2.64	1.29	-1.11
Sorbitol	5	3.97	3.09	1.28	-1.12
Pyelonephritis	5	3.56	2.77	1.28	-1.12
Alopecia	5	4.15	3.24	1.28	-1.12
Anoxia	5	4.23	3.30	1.28	-1.12
Bacteremia	5	3.98	3.12	1.28	-1.12
Cardiotoxicity	5	3.47	2.72	1.28	-1.12
Chlorine	5	3.81	3.01	1.27	-1.13
Digitonin	5	3.73	2.95	1.27	-1.13
Brain Infarction	5	4.40	3.48	1.27	-1.13
Salicylate	5	4.57	3.64	1.26	-1.14
Methylprednisolone	5	4.83	3.85	1.26	-1.14

FIG. 27-29

POMC	5	3.48	2.77	1.25	-1.15
Carbon Monoxide	5	4.56	3.67	1.24	-1.16
Lithium Chloride	5	3.74	3.03	1.23	-1.17
ATPase	5	3.57	2.91	1.23	-1.17
calcium channel	5	4.65	3.82	1.22	-1.18
INSULIN-DEPENDENT DIABETES MELLITUS	5	4.54	3.73	1.22	-1.18
Tachycardia	5	4.85	4.04	1.20	-1.20
Chymotrypsin	5	4.79	4.00	1.20	-1.20
Liver Failure	5	3.73	3.12	1.20	-1.20
Lipase	5	4.57	3.84	1.19	-1.21
Pyrimidine	5	4.55	3.82	1.19	-1.21
Leukopenia	5	4.09	3.44	1.19	-1.21
Cyanogen Bromide	5	4.36	3.68	1.19	-1.21
Uric Acid	5	4.47	3.80	1.18	-1.22
5,10-METHYLENETETRAHYDROFOLATE REDUCTASE	5	3.91	3.34	1.17	-1.23
Cyclic Nucleotides	5	3.31	2.84	1.17	-1.23
Cyclosporine	5	4.76	4.22	1.13	-1.27
Hydroxylamine	5	3.74	3.35	1.11	-1.29
Anticoagulant	5	4.96	4.52	1.10	-1.30
Nephrotic Syndrome	5	3.74	3.42	1.09	-1.31
Lidocaine	5	4.94	4.54	1.09	-1.31
Fructose	5	4.16	3.83	1.09	-1.31
Choline	5	4.82	4.47	1.08	-1.32
Dementia	5	4.57	4.26	1.07	-1.33
Cytochrome P-450	5	4.65	4.33	1.07	-1.33
Chloroform	5	4.35	4.06	1.07	-1.33
Mannitol	5	4.57	4.26	1.07	-1.33
Dopamine Receptors	5	3.40	3.19	1.07	-1.33
Carbon Dioxide	5	4.62	4.36	1.06	-1.34
Lupus	5	4.37	4.13	1.06	-1.34
Ataxia	5	4.75	4.50	1.06	-1.34
Hydroxide	5	3.78	3.60	1.05	-1.35
C-Peptide	5	2.74	2.62	1.05	-1.35
Nitroprusside	5	3.79	3.63	1.04	-1.36
Cyanide	5	3.91	3.76	1.04	-1.36
Mesothelioma	5	2.58	2.49	1.03	-1.37
Paclitaxel	5	2.57	2.49	1.03	-1.37
Trifluoperazine	5	3.15	3.07	1.02	-1.38
Gentamicin	5	3.70	3.62	1.02	-1.38
Calcium Channels	5	3.46	3.48	1.00	-1.40
TRH	5	3.58	3.59	0.99	-1.41
Phenobarbital	5	4.40	4.54	0.97	-1.43
Malaria	5	3.72	3.85	0.97	-1.43
Naloxone	5	3.47	3.60	0.96	-1.44
Convulsions	5	4.33	4.54	0.95	-1.45
Radioisotope	5	3.33	3.62	0.92	-1.48
Ouabain	5	3.52	3.84	0.92	-1.48
AVP	5	3.55	3.88	0.91	-1.49
Mental Retardation	5	4.32	4.73	0.91	-1.49
Cimetidine	5	3.58	3.93	0.91	-1.49
TACHYKININ 1	5	3.82	4.22	0.91	-1.49
Confusion	5	4.15	4.65	0.89	-1.51

FIG. 27-30

PRTS	5	4.16	4.80	0.87	-1.53
Fluoride	5	3.55	4.32	0.82	-1.58
Prednisone	5	3.40	4.37	0.78	-1.62
Lithium	5	3.23	4.40	0.73	-1.67
Telomerase	5	1.58	2.15	0.73	-1.67
Etoposide	5	2.57	3.61	0.71	-1.69
MMP2	5	1.83	2.68	0.68	-1.72
PLAU	5	1.99	3.40	0.58	-1.82
Fractures	5	2.76	4.94	0.56	-1.84
ETV1	4	3.87	1.13	3.41	0.61
TIMP4	4	3.97	1.18	3.38	0.58
SDF1	4	3.96	1.19	3.32	0.52
CELLULAR SENESCENCE-RELATED 1	4	3.72	1.16	3.21	0.41
MAD2L1	4	3.77	1.21	3.13	0.33
LAMR1	4	3.99	1.28	3.12	0.32
TELOMERE REVERSE TRANSCRIPTASE	4	3.88	1.25	3.11	0.31
S100A4	4	3.83	1.23	3.11	0.31
IGF1R	4	3.92	1.26	3.10	0.30
THBS2	4	3.62	1.17	3.09	0.29
BACULOVIRAL IAP REPEAT-CONTAINING PROTEIN 5	4	3.98	1.30	3.07	0.27
FIGF	4	3.55	1.16	3.07	0.27
XLKD1	4	3.33	1.09	3.06	0.26
FBLN1	4	3.51	1.16	3.02	0.22
PEA15	4	3.47	1.16	3.00	0.20
FOXO1A	4	3.74	1.26	2.98	0.18
MAP2K4	4	3.47	1.17	2.96	0.16
BMP6	4	3.80	1.28	2.96	0.16
EDG2	4	3.57	1.21	2.94	0.14
Angiogenesis Factor	4	3.94	1.34	2.94	0.14
MMP14	4	3.75	1.28	2.94	0.14
MDK	4	3.99	1.36	2.93	0.13
TERT	4	3.82	1.31	2.92	0.12
SCYA21	4	3.49	1.20	2.91	0.11
CTNNG	4	3.83	1.32	2.89	0.09
RAP1A	4	3.85	1.33	2.89	0.09
Phyllodes Tumor	4	3.40	1.18	2.89	0.09
BRCD2	4	3.41	1.18	2.88	0.08
PROTEASE INHIBITOR 5	4	3.58	1.24	2.88	0.08
DAD1	4	3.45	1.20	2.88	0.08
CTGF	4	3.97	1.41	2.82	0.02
GRO1	4	3.79	1.35	2.80	0.00
Adenosarcoma	4	3.41	1.21	2.80	0.00
Mucinous Cystadenoma	4	3.91	1.40	2.80	0.00
AREG	4	3.99	1.43	2.79	-0.01
BREAST CANCER ANTIESTROGEN RESISTANCE 1	4	3.76	1.35	2.79	-0.01
DECAPENTAPLEGIC 2	4	3.96	1.42	2.78	-0.02
TEP1	4	3.55	1.28	2.77	-0.03
PLACENTAL GROWTH FACTOR	4	3.38	1.22	2.76	-0.04
KRT20	4	3.65	1.33	2.75	-0.05
THBS1	4	3.65	1.33	2.75	-0.05
RET PROTOONCOGENE	4	3.39	1.23	2.74	-0.06
DECAPENTAPLEGIC 3	4	3.79	1.39	2.73	-0.07

FIG. 27-31



SOLUBLE BETA-GALACTOSIDE BINDING LECTIN 1	4	3.79	1.39	2.73	-0.07
MKI67	4	3.58	1.31	2.73	-0.07
APR-2	4	3.90	1.44	2.71	-0.09
TP73	4	4.00	1.48	2.71	-0.09
Estrogen Antagonists	4	3.37	1.25	2.70	-0.10
wnt-1	4	3.75	1.39	2.70	-0.10
AXL	4	3.45	1.28	2.69	-0.11
FGF8	4	3.82	1.43	2.68	-0.12
MMP8	4	3.72	1.39	2.68	-0.12
FKSG2	4	3.57	1.33	2.68	-0.12
Neurocytoma	4	3.30	1.23	2.67	-0.13
MSN	4	3.79	1.42	2.67	-0.13
FAMILIAL CANCER	4	3.76	1.41	2.67	-0.13
JUP	4	3.98	1.49	2.66	-0.14
ITGB4	4	3.50	1.32	2.66	-0.14
MYCL1	4	3.16	1.19	2.65	-0.15
FHIT	4	3.58	1.35	2.65	-0.15
FGF4	4	3.99	1.51	2.65	-0.15
IGSF2	4	3.50	1.32	2.65	-0.15
MULTIPLE LIPOMAS MACROCEPHALY	4	3.08	1.16	2.64	-0.16
PAWR	4	3.52	1.33	2.64	-0.16
INHIBITOR OF DNA BINDING 1	4	3.37	1.28	2.64	-0.16
COWDEN DISEASE	4	3.40	1.29	2.63	-0.17
HIC1	4	2.98	1.14	2.62	-0.18
SSTR2	4	3.50	1.34	2.62	-0.18
PECAM1	4	3.57	1.36	2.62	-0.18
WNT3	4	2.97	1.14	2.61	-0.19
NRG1	4	3.38	1.30	2.61	-0.19
EFS2	4	3.45	1.33	2.61	-0.19
BRCA1 Protein	4	3.16	1.21	2.60	-0.20
S100A6	4	3.66	1.40	2.60	-0.20
Lignan	4	3.77	1.45	2.60	-0.20
Papillomavirus Infection	4	3.91	1.51	2.60	-0.20
TYPE 2 PLASMINOGEN ACTIVATOR INHIBITOR	4	3.23	1.25	2.59	-0.21
CEACAM1	4	3.77	1.45	2.59	-0.21
Serous Cystadenoma	4	3.22	1.24	2.59	-0.21
HOXA1	4	2.98	1.15	2.59	-0.21
RAF1	4	3.78	1.47	2.58	-0.22
Fucosyltransferase	4	3.80	1.47	2.58	-0.22
Neurofibrosarcoma	4	3.40	1.32	2.58	-0.22
SLC6A10	4	3.35	1.30	2.57	-0.23
Calcitonin Receptors	4	3.40	1.32	2.57	-0.23
WNT5A	4	2.98	1.17	2.54	-0.26
TBX2	4	2.96	1.17	2.53	-0.27
SCYC1	4	3.37	1.34	2.53	-0.27
MET	4	2.97	1.18	2.52	-0.28
KRT5	4	3.34	1.32	2.52	-0.28
WNT10B	4	2.81	1.12	2.51	-0.29
CCR7	4	3.16	1.26	2.51	-0.29
Colonic Polyps	4	3.94	1.57	2.51	-0.29
Estramustine	4	3.75	1.50	2.49	-0.31
Hypothalamic Hormones	4	3.40	1.37	2.49	-0.31

FIG. 27-32

CCNG1	4	3.07	1.24	2.48	-0.32
Anthrax	4	3.87	1.56	2.48	-0.32
Disintegrin	4	3.79	1.53	2.48	-0.32
REGULATOR OF CHROMATIN MATRIX-ASSOCIATED	4	3.80	1.53	2.48	-0.32
BWS	4	3.74	1.52	2.47	-0.33
MLANA	4	3.24	1.31	2.47	-0.33
TITF1	4	3.41	1.39	2.46	-0.34
Keratoacanthoma	4	3.81	1.55	2.46	-0.34
WILMS TUMOR AND PSEUDOHERMAPHRODITISM	4	3.05	1.24	2.45	-0.35
MYCN	4	3.58	1.46	2.45	-0.35
ADENOMYOSIS	4	3.62	1.48	2.45	-0.35
ST7	4	3.40	1.39	2.44	-0.36
MYOD1	4	3.46	1.42	2.43	-0.37
Ganglioneuroblastoma	4	3.62	1.49	2.43	-0.37
Bioflavonoid	4	3.51	1.45	2.43	-0.37
RRM1	4	2.82	1.16	2.43	-0.37
GATA3	4	2.81	1.16	2.42	-0.38
Hemangiosarcoma	4	3.40	1.41	2.41	-0.39
STATHMIN 1	4	3.24	1.34	2.41	-0.39
MMP7	4	3.40	1.41	2.41	-0.39
CATALYTIC SUBUNIT DNA-ACTIVATED PROTEIN KINASE	4	3.75	1.56	2.40	-0.40
Azoxymethane	4	3.94	1.64	2.40	-0.40
Mucinous Cystadenocarcinoma	4	3.33	1.40	2.39	-0.41
CCND3	4	3.57	1.50	2.38	-0.42
COL1A1	4	3.37	1.41	2.38	-0.42
X-LINKED IMMUNODEFICIENCY	4	3.74	1.57	2.38	-0.42
ONCOCYTOMA	4	3.48	1.46	2.38	-0.42
FGFR4	4	2.71	1.14	2.38	-0.42
MC1R	4	2.98	1.25	2.38	-0.42
Bispecific Antibodies	4	3.37	1.42	2.37	-0.43
MGMT	4	3.52	1.48	2.37	-0.43
KLK11	4	3.21	1.35	2.37	-0.43
Stromelysin 1	4	3.93	1.66	2.37	-0.43
THRB	4	2.99	1.26	2.37	-0.43
CNR2	4	3.59	1.51	2.37	-0.43
Neurofibromatosis 2	4	2.99	1.26	2.36	-0.44
Methylazoxymethanol Acetate	4	3.13	1.33	2.36	-0.44
FACTOR	4	3.00	1.27	2.36	-0.44
RARA	4	3.56	1.51	2.35	-0.45
Angiofibroma	4	3.51	1.49	2.35	-0.45
FGF5	4	2.98	1.27	2.35	-0.45
ILK	4	3.38	1.44	2.35	-0.45
PRB2	4	2.74	1.16	2.35	-0.45
ADP-Ribosylation Factors	4	3.48	1.49	2.34	-0.46
CALCR	4	3.41	1.46	2.34	-0.46
HDAC1	4	3.71	1.59	2.34	-0.46
MCCUNE-ALBRIGHT SYNDROME	4	3.37	1.45	2.33	-0.47
THROMBOSPONDIN II	4	2.74	1.17	2.33	-0.47
FST	4	3.80	1.63	2.33	-0.47
ANGPT2	4	2.92	1.25	2.33	-0.47
Catechol Estrogens	4	3.55	1.53	2.32	-0.48
ADULT FOLATE RECEPTOR 1	4	3.23	1.39	2.32	-0.48

FIG. 27-33

ANGPT1	4	2.99	1.30	2.30	-0.50
ETS1	4	3.09	1.35	2.29	-0.51
Calmodulin-Binding Proteins	4	3.21	1.40	2.29	-0.51
Neoplastic Processes	4	3.68	1.61	2.29	-0.51
Theobromine	4	3.79	1.66	2.29	-0.51
F11	4	3.59	1.57	2.28	-0.52
Myeloid Metaplasia	4	3.58	1.57	2.28	-0.52
Gliosarcoma	4	3.65	1.60	2.28	-0.52
MULTIPLE LIPOMATOSIS	4	3.06	1.35	2.28	-0.52
MELANOMA NCK PROTEIN	4	3.09	1.37	2.26	-0.54
RDX	4	3.16	1.40	2.25	-0.55
KLK1	4	2.56	1.14	2.25	-0.55
MAPK9	4	3.47	1.54	2.25	-0.55
ALPHA-1 TYPE XVIII COLLAGEN	4	2.97	1.32	2.25	-0.55
Anovulation	4	3.55	1.58	2.24	-0.56
Interleukin-13	4	3.50	1.56	2.24	-0.56
NOP56	4	3.54	1.59	2.24	-0.56
OCLN	4	3.23	1.45	2.23	-0.57
CASR	4	3.20	1.44	2.23	-0.57
Activin Receptors	4	3.12	1.41	2.22	-0.58
ADM	4	3.83	1.73	2.22	-0.58
Symporter	4	3.68	1.66	2.21	-0.59
YY1	4	3.56	1.61	2.21	-0.59
CYSTEINE- AND GLYCINE-RICH PROTEIN 1	4	3.47	1.57	2.21	-0.59
POU1F1	4	3.01	1.36	2.21	-0.59
THYROID-STIMULATING HORMONE RECEPTOR	4	3.57	1.62	2.21	-0.59
SCP2	4	2.95	1.34	2.20	-0.60
Myoma	4	3.80	1.73	2.20	-0.60
70-KD THYROID AUTOANTIGEN	4	2.96	1.35	2.20	-0.60
SUPERFAMILY	4	3.16	1.44	2.20	-0.60
INHBA	4	3.90	1.77	2.20	-0.60
TALIN	4	3.71	1.69	2.20	-0.60
Cushing Syndrome	4	3.23	1.48	2.19	-0.61
Bradykinin Receptors	4	3.72	1.70	2.19	-0.61
Interleukin-15	4	2.96	1.36	2.17	-0.63
Synthetic Estrogens	4	2.98	1.38	2.17	-0.63
Buserelin	4	3.40	1.57	2.17	-0.63
S-ADENOSYLMETHIONINE DECARBOXYLASE	4	3.37	1.56	2.17	-0.63
SLC4A3	4	3.65	1.69	2.16	-0.64
COL1AR	4	3.37	1.56	2.16	-0.64
BETA-2 GAP JUNCTION PROTEIN	4	3.20	1.48	2.16	-0.64
Leukoplakia	4	3.56	1.65	2.16	-0.64
INDUCIBLE GENE GADD45	4	3.37	1.57	2.15	-0.65
Catechin	4	3.78	1.76	2.15	-0.65
Acoustic Neuroma	4	3.37	1.57	2.15	-0.65
Corneal Neovascularization	4	3.15	1.47	2.15	-0.65
STAT6	4	3.16	1.47	2.14	-0.66
FOLLICULAR THYROID CARCINOMA	4	2.94	1.37	2.14	-0.66
IL6R	4	3.32	1.56	2.14	-0.66
1-Methyl-3-isobutylxanthine	4	3.41	1.59	2.14	-0.66
Peplomycin	4	3.16	1.48	2.14	-0.66
Somalomedin	4	3.65	1.71	2.14	-0.66

FIG. 27-34

Angiogenesis Inhibitors	4	2.99	1.40	2.13	-0.67
P29	4	3.24	1.52	2.13	-0.67
KAPOSI SARCOMA	4	3.57	1.67	2.13	-0.67
BETA PROTEIN-TYROSINE KINASE 2	4	3.20	1.50	2.13	-0.67
Taq Polymerase	4	3.21	1.51	2.13	-0.67
NCOA1	4	2.98	1.40	2.13	-0.67
Dieldrin	4	3.79	1.78	2.12	-0.68
Factor VIIa	4	3.81	1.79	2.12	-0.68
ANXA2	4	3.37	1.59	2.12	-0.68
AMYLOID BETA A4 PRECURSOR PROTEIN	4	3.05	1.44	2.12	-0.68
TAP1	4	3.05	1.44	2.12	-0.68
TPO	4	3.82	1.80	2.12	-0.68
TEK	4	3.00	1.42	2.12	-0.68
Ganglioglioma	4	2.99	1.41	2.12	-0.68
ZAP70	4	3.31	1.57	2.11	-0.69
Sodium Iodide	4	3.47	1.65	2.11	-0.69
Heparinoid	4	2.81	1.33	2.11	-0.69
COLONY-STIMULATING FACTOR 1 RECEPTOR	4	2.71	1.29	2.10	-0.70
Histone acetylation	4	3.58	1.70	2.10	-0.70
SMALL CELL CANCER OF THE LUNG	4	2.74	1.31	2.10	-0.70
TP63	4	2.91	1.39	2.10	-0.70
Etretinate	4	3.67	1.76	2.09	-0.71
alpha-Linolenic Acid	4	3.51	1.68	2.09	-0.71
Gingival Hyperplasia	4	3.20	1.54	2.09	-0.71
GTPase-Activating Proteins	4	2.95	1.42	2.08	-0.72
SSTR5	4	2.56	1.23	2.08	-0.72
KRT13	4	3.32	1.59	2.08	-0.72
Aldrin	4	3.20	1.54	2.08	-0.72
Subacute Thyroiditis	4	2.95	1.42	2.08	-0.72
Matrilysin	4	2.97	1.43	2.07	-0.73
Distamycin	4	3.33	1.61	2.07	-0.73
P2Y5	4	3.24	1.56	2.07	-0.73
CDKN1C	4	3.16	1.52	2.07	-0.73
RETICULUM CELL SARCOMA	4	3.23	1.56	2.07	-0.73
Low-Grade Lymphoma	4	2.96	1.43	2.07	-0.73
Osteopetrosis	4	3.97	1.92	2.06	-0.74
APRT	4	3.64	1.77	2.06	-0.74
GYS1	4	2.74	1.33	2.06	-0.74
BRAIN CYTOPLASMIC 1	4	3.23	1.57	2.06	-0.74
Thymosin	4	3.97	1.93	2.05	-0.75
MYOSIN LIGHT CHAIN KINASE	4	3.23	1.58	2.05	-0.75
MT2A	4	3.56	1.74	2.04	-0.76
Neuraminic Acids	4	3.61	1.77	2.04	-0.76
DNA METHYLTRANSFERASE 1	4	3.51	1.73	2.03	-0.77
alpha-L-Fucosidase	4	3.16	1.56	2.03	-0.77
FASN	4	3.65	1.80	2.03	-0.77
DBI	4	3.06	1.51	2.03	-0.77
CTSL	4	3.82	1.89	2.03	-0.77
SRF	4	3.20	1.58	2.02	-0.78
Catechol O-Methyltransferase	4	3.37	1.67	2.02	-0.78
MVP	4	3.52	1.74	2.02	-0.78
Osteoma	4	3.09	1.53	2.02	-0.78

FIG. 27-35

SCG2	4	2.95	1.46	2.02	-0.78
Selenomethionine	4	3.40	1.68	2.02	-0.78
Ovarian Cysts	4	3.51	1.74	2.01	-0.79
APOD	4	2.74	1.36	2.01	-0.79
Croton Oil	4	3.37	1.68	2.01	-0.79
MEMBER 1 SUBFAMILY C ATP-BINDING CASSETTE	4	3.79	1.89	2.00	-0.80
Lymphoblastic Lymphoma	4	3.33	1.66	2.00	-0.80
Pneumoconiosis	4	3.31	1.66	1.99	-0.81
CD47	4	2.81	1.41	1.99	-0.81
JUND	4	3.46	1.74	1.99	-0.81
Gastrinoma	4	2.97	1.49	1.99	-0.81
COMT	4	3.87	1.95	1.99	-0.81
GIP	4	3.75	1.89	1.98	-0.82
Cystatin	4	3.23	1.63	1.98	-0.82
ANGIOGENIN	4	3.00	1.51	1.98	-0.82
BETA-1 GAP JUNCTION PROTEIN	4	3.16	1.60	1.98	-0.82
Dimethylhydrazine	4	3.16	1.60	1.98	-0.82
Seborrheic Keratosis	4	2.56	1.30	1.97	-0.83
PROTEIN 1	4	3.23	1.64	1.97	-0.83
Feline Leukemia	4	3.23	1.64	1.97	-0.83
PERNICIOUS ANEMIA	4	3.46	1.76	1.97	-0.83
FACTOR D	4	3.22	1.64	1.97	-0.83
Drosophila Proteins	4	3.33	1.70	1.96	-0.84
DECAPENTAPLEGIC 4	4	2.99	1.53	1.96	-0.84
Immunotoxin	4	3.64	1.87	1.95	-0.85
LH Receptors	4	2.98	1.53	1.95	-0.85
Fenretinide	4	2.47	1.27	1.95	-0.85
ACP2	4	2.96	1.52	1.95	-0.85
CONTACTIN-ASSOCIATED PROTEIN 1	4	2.96	1.52	1.95	-0.85
Prostaglandin-Endoperoxide Synthase	4	2.67	1.37	1.94	-0.86
Simvastatin	4	3.81	1.96	1.94	-0.86
ALY	4	3.10	1.60	1.94	-0.86
CYTOTOXIC T LYMPHOCYTE-ASSOCIATED 4	4	3.20	1.65	1.94	-0.86
ATF2	4	3.37	1.74	1.94	-0.86
Microtubule-Associated Proteins	4	3.43	1.77	1.94	-0.86
IAPP	4	3.55	1.84	1.94	-0.86
STN	4	3.36	1.74	1.93	-0.87
Secondary Hyperparathyroidism	4	3.90	2.02	1.93	-0.87
HRPT2	4	3.32	1.72	1.93	-0.87
Placental Extracts	4	2.92	1.52	1.92	-0.88
Pelvic Pain	4	3.47	1.81	1.92	-0.88
Selectin	4	3.51	1.84	1.91	-0.89
IMMEDIATE-EARLY RESPONSE 3	4	2.56	1.34	1.91	-0.89
Arsenical	4	2.98	1.56	1.91	-0.89
GPD1	4	2.81	1.48	1.90	-0.90
P125	4	2.57	1.35	1.90	-0.90
Selenious Acid	4	3.92	2.06	1.90	-0.90
Lymphotoxin	4	3.78	1.99	1.90	-0.90
Interferon Receptors	4	2.32	1.22	1.90	-0.90
CREBBP	4	2.57	1.35	1.90	-0.90
Procarbazine	4	3.55	1.87	1.90	-0.90
KELOIDS	4	2.99	1.57	1.90	-0.90

FIG. 27-36

Ureteral Obstruction	4	3.79	2.00	1.90	-0.90
GHR	4	3.15	1.67	1.89	-0.91
CASP3	4	3.37	1.78	1.89	-0.91
Proteome	4	3.10	1.64	1.89	-0.91
Acetyl-CoA Carboxylase	4	3.37	1.79	1.89	-0.91
Nasal Polyps	4	3.55	1.88	1.89	-0.91
Methylnitrosourea	4	3.93	2.08	1.88	-0.92
GDNF	4	3.23	1.72	1.88	-0.92
Molecular Chaperones	4	3.52	1.87	1.88	-0.92
INSM1	4	2.74	1.46	1.88	-0.92
Factor XIIIa	4	3.41	1.81	1.88	-0.92
Stilbene	4	3.79	2.02	1.88	-0.92
CTF1	4	2.74	1.46	1.88	-0.92
Properdin	4	3.15	1.68	1.88	-0.92
FCGR1A	4	2.98	1.59	1.88	-0.92
Gigantism	4	2.81	1.50	1.87	-0.93
Deoxycholic Acid	4	3.65	1.95	1.87	-0.93
ALPHA II DNA TOPOISOMERASE	4	3.47	1.86	1.87	-0.93
1-Butanol	4	3.21	1.72	1.87	-0.93
GSN	4	3.51	1.88	1.87	-0.93
CSN1	4	2.95	1.59	1.86	-0.94
Methylcholanthrene	4	3.33	1.79	1.86	-0.94
GLS	4	3.72	2.00	1.86	-0.94
UGB	4	2.98	1.60	1.86	-0.94
TYPE II MATURITY-ONSET DIABETES OF THE YOUNG	4	3.38	1.82	1.85	-0.95
Troponin	4	3.41	1.84	1.85	-0.95
Osteomalacia	4	3.77	2.04	1.85	-0.95
CD80	4	3.75	2.03	1.85	-0.95
Mevalonic Acid	4	2.96	1.60	1.85	-0.95
Intestinal Disease	4	3.30	1.79	1.84	-0.96
Papillary Adenocarcinoma	4	2.96	1.61	1.84	-0.96
DCN	4	3.50	1.90	1.84	-0.96
Mannosidase	4	3.05	1.66	1.84	-0.96
S8	4	2.99	1.63	1.84	-0.96
Pyruvic Acid	4	3.38	1.85	1.83	-0.97
Troponin I	4	3.21	1.76	1.83	-0.97
MYXEDEMA	4	2.99	1.64	1.82	-0.98
Superantigen	4	3.63	1.99	1.82	-0.98
CA2	4	3.31	1.82	1.82	-0.98
Autoimmune Thyroiditis	4	3.49	1.92	1.82	-0.98
Benzophenone	4	2.96	1.63	1.82	-0.98
Streptozocin	4	3.23	1.78	1.82	-0.98
Linolenic Acids	4	3.76	2.07	1.81	-0.99
NCL	4	3.05	1.69	1.81	-0.99
Dysmenorrhea	4	2.91	1.61	1.81	-0.99
FIH	4	3.90	2.16	1.81	-0.99
Pyrimidine Nucleotides	4	3.23	1.79	1.80	-1.00
Peptide Receptors	4	3.23	1.80	1.80	-1.00
Oxonic Acid	4	3.57	1.98	1.80	-1.00
TRAF3	4	2.56	1.43	1.79	-1.01
Hypomethylation	4	3.58	2.00	1.79	-1.01
RE2	4	3.13	1.75	1.79	-1.01

FIG. 27-37

TOBACCO ADDICTION	4	3.64	2.03	1.79	-1.01
PPY	4	3.96	2.21	1.79	-1.01
THBD	4	3.99	2.23	1.79	-1.01
Endothelin-3	4	2.92	1.64	1.78	-1.02
Dietary Calcium	4	3.32	1.87	1.77	-1.03
chromosomal translocation	4	3.99	2.25	1.77	-1.03
Asialoglycoprotein	4	3.50	1.97	1.77	-1.03
GRO2	4	3.13	1.77	1.77	-1.03
Actomyosin	4	3.57	2.02	1.77	-1.03
Pravastatin	4	3.21	1.82	1.77	-1.03
Ramipril	4	2.81	1.59	1.77	-1.03
Bullous Pemphigoid	4	3.49	1.98	1.76	-1.04
Hypophosphatemia	4	3.50	1.98	1.76	-1.04
CALR	4	3.34	1.89	1.76	-1.04
Famotidine	4	3.93	2.23	1.76	-1.04
Soybean Oil	4	3.40	1.93	1.76	-1.04
MAST CELL DISEASE	4	3.47	1.98	1.76	-1.04
ADRENAL HYPERPLASIA	4	2.56	1.46	1.75	-1.05
SLC2A2	4	2.74	1.57	1.75	-1.05
GRP	4	3.96	2.27	1.74	-1.06
S-Nitroso-N-Acetylpenicillamine	4	3.54	2.03	1.74	-1.06
Danazol	4	3.57	2.05	1.74	-1.06
Topotecan	4	2.81	1.61	1.74	-1.06
MYOGENIC DIFFERENTIATION ANTIGEN 1	4	3.40	1.95	1.74	-1.06
Exophthalmos	4	3.23	1.87	1.72	-1.08
Nitrogen Dioxide	4	3.24	1.88	1.72	-1.08
TARTRATE-RESISTANT TYPE 5 ACID PHOSPHATASE	4	3.33	1.94	1.72	-1.08
Polymethyl Methacrylate	4	3.52	2.05	1.72	-1.08
Histamine Receptors	4	3.23	1.89	1.71	-1.09
MYCOSIS FUNGOIDES	4	3.57	2.08	1.71	-1.09
Pancreatic Hormones	4	2.67	1.56	1.71	-1.09
NME2	4	2.16	1.26	1.71	-1.09
Pseudopregnancy	4	2.99	1.75	1.71	-1.09
FIBROSARCOMA ONCOGENE FAMILY	4	3.16	1.85	1.70	-1.10
HEREDITARY SPHEROCYTOSIS	4	2.74	1.61	1.70	-1.10
Xeroderma Pigmentosum	4	3.50	2.06	1.70	-1.10
Ankyrin	4	3.52	2.08	1.69	-1.11
ALPHA-1 MICROGLOBULIN/BIKUNIN PRECURSOR	4	2.81	1.66	1.69	-1.11
Resorcinol	4	2.95	1.75	1.69	-1.11
ALPP	4	3.51	2.07	1.69	-1.11
Polycythemia	4	3.51	2.08	1.68	-1.12
CD38	4	3.33	1.98	1.68	-1.12
B9	4	2.98	1.78	1.68	-1.12
CD7	4	3.06	1.82	1.68	-1.12
Megestrol Acetate	4	2.65	1.58	1.68	-1.12
Berberine	4	3.40	2.03	1.68	-1.12
Brain Disease	4	2.98	1.79	1.67	-1.13
S-Nitrosoglutathione	4	2.81	1.70	1.66	-1.14
Pro-Opiomelanocortin	4	2.98	1.80	1.66	-1.14
IRS2	4	2.40	1.45	1.66	-1.14
DNA Adducts	4	3.79	2.29	1.65	-1.15
Histoplasmosis	4	3.31	2.01	1.65	-1.15

FIG. 27-38

ENPP3	4	3.54	2.15	1.64	-1.16
CYP1B1	4	3.34	2.03	1.64	-1.16
Trypsinogen	4	2.98	1.82	1.64	-1.16
Somatostatin Receptors	4	3.00	1.83	1.64	-1.16
G17	4	3.74	2.29	1.63	-1.17
Silicone Oils	4	2.71	1.66	1.63	-1.17
APC	4	2.58	1.59	1.63	-1.17
CDK5	4	2.32	1.43	1.62	-1.18
Ficoll	4	3.82	2.35	1.62	-1.18
Bezafibrate	4	2.73	1.68	1.62	-1.18
Phorbol 12,13-Dibutyrate	4	3.98	2.46	1.62	-1.18
Ribonucleotide Reductases	4	3.65	2.26	1.62	-1.18
Sucralfate	4	2.99	1.85	1.62	-1.18
Histone H1	4	3.74	2.32	1.61	-1.19
HIV Protease	4	2.71	1.69	1.61	-1.19
Pentagastrin	4	3.57	2.23	1.61	-1.19
Coagulant	4	3.42	2.13	1.61	-1.19
Fibroma	4	3.40	2.12	1.60	-1.20
PROTEUS SYNDROME	4	2.91	1.82	1.60	-1.20
SPN	4	3.06	1.91	1.60	-1.20
Antipain	4	2.92	1.82	1.60	-1.20
Cathepsin	4	3.79	2.37	1.60	-1.20
Nitrosamine	4	3.62	2.27	1.59	-1.21
NHC	4	2.32	1.46	1.59	-1.21
PP	4	2.99	1.88	1.59	-1.21
RETINAL DETACHMENT	4	3.90	2.45	1.59	-1.21
Spectrin	4	3.74	2.36	1.59	-1.21
Plague	4	3.09	1.95	1.58	-1.22
ACUTE MYELOCYTIC LEUKEMIA	4	2.74	1.73	1.58	-1.22
SAA1	4	3.08	1.95	1.58	-1.22
PAPILLARY THYROID CARCINOMA	4	2.58	1.63	1.58	-1.22
Carboxymethylcellulose	4	3.30	2.09	1.58	-1.22
Cardiomegaly	4	3.62	2.29	1.58	-1.22
MALIGNANT MESOTHELIOMA	4	3.00	1.90	1.57	-1.23
Halogen	4	3.44	2.19	1.57	-1.23
HPSE	4	2.16	1.38	1.57	-1.23
Pleurisy	4	3.41	2.18	1.56	-1.24
Clotrimazole	4	3.33	2.13	1.56	-1.24
Gastrointestinal Hemorrhage	4	3.23	2.07	1.56	-1.24
Benzoquinone	4	2.91	1.86	1.56	-1.24
GRAVES DISEASE	4	3.90	2.50	1.56	-1.24
Phosphorylcholine	4	3.37	2.16	1.56	-1.24
AHR	4	2.57	1.65	1.56	-1.24
Viologen	4	2.71	1.74	1.56	-1.24
Tin	4	3.82	2.45	1.56	-1.24
GSTP1	4	2.83	1.82	1.56	-1.24
Triamcinolone Acetonide	4	3.21	2.07	1.56	-1.24
ALPHA-1 TYPE II COLLAGEN	4	3.58	2.31	1.55	-1.25
Anorexia Nervosa	4	3.51	2.27	1.55	-1.25
GAP43	4	3.15	2.04	1.55	-1.25
Impotence	4	3.83	2.48	1.54	-1.26
CRH	4	3.74	2.42	1.54	-1.26

FIG. 27-39



BETA-3 INTEGRIN	4	2.57	1.67	1.54	-1.26
CS	4	3.45	2.23	1.54	-1.26
FUT3	4	3.34	2.16	1.54	-1.26
Surface Immunoglobulins	4	3.50	2.27	1.54	-1.26
TAT	4	3.13	2.03	1.54	-1.26
Liver Glycogen	4	3.15	2.05	1.54	-1.26
Infectious Mononucleosis	4	3.32	2.17	1.53	-1.27
Paraprotein	4	3.01	1.97	1.53	-1.27
VEGFC	4	1.97	1.29	1.52	-1.28
Phosphofructokinase-1	4	2.81	1.85	1.52	-1.28
Cytotoxin	4	3.75	2.48	1.51	-1.29
EPHX1	4	3.40	2.24	1.51	-1.29
PSEUDONEONATAL ADRENOLEUKODYSTROPHY	4	2.67	1.76	1.51	-1.29
FCGR3A	4	3.64	2.41	1.51	-1.29
Arachidonic Acids	4	2.57	1.70	1.51	-1.29
Potassium Permanganate	4	2.71	1.80	1.51	-1.29
Interleukin-5	4	2.91	1.93	1.51	-1.29
Succinic Acid	4	3.13	2.08	1.50	-1.30
CD33	4	3.23	2.15	1.50	-1.30
Thiamine Deficiency	4	2.67	1.78	1.50	-1.30
FAMILIAL HYPERCHOLESTEROLEMIA	4	2.91	1.94	1.50	-1.30
Neuroendocrine Carcinoma	4	2.37	1.58	1.50	-1.30
PFDN5	4	3.09	2.06	1.50	-1.30
Sulfone	4	3.56	2.39	1.49	-1.31
Disease Susceptibility	4	3.23	2.16	1.49	-1.31
Glucose Intolerance	4	3.75	2.52	1.49	-1.31
IMMUNE SUPPRESSION	4	3.58	2.41	1.49	-1.31
Sclerosing Cholangitis	4	2.98	2.01	1.49	-1.31
ATAXIA-TELANGIECTASIA	4	2.57	1.73	1.48	-1.32
Glucan	4	3.33	2.25	1.48	-1.32
Dimyristoylphosphatidylcholine	4	3.15	2.13	1.48	-1.32
Dermatomyositis	4	3.51	2.37	1.48	-1.32
Thioacetamide	4	2.81	1.90	1.48	-1.32
p100	4	2.99	2.02	1.48	-1.32
PCOS1	4	2.50	1.69	1.48	-1.32
Glutathione Transferase	4	3.08	2.09	1.48	-1.32
Pyrene	4	3.39	2.30	1.47	-1.33
Stearate	4	3.45	2.34	1.47	-1.33
RNU1G4	4	3.24	2.20	1.47	-1.33
Sodium Selenite	4	3.05	2.09	1.46	-1.34
DIANPH	4	3.75	2.57	1.46	-1.34
Snake Venoms	4	3.82	2.62	1.45	-1.35
Ethinyl Estradiol	4	3.23	2.23	1.45	-1.35
Thrombocytosis	4	3.39	2.34	1.45	-1.35
Neurofilament Proteins	4	3.26	2.26	1.44	-1.36
Benzoic Acid	4	3.89	2.70	1.44	-1.36
EPHRIN RECEPTOR EphA3	4	3.79	2.64	1.44	-1.36
DPP4	4	2.81	1.96	1.44	-1.36
Methimazole	4	3.48	2.42	1.44	-1.36
Antiporter	4	3.23	2.25	1.43	-1.37
SECTM1	4	3.97	2.77	1.43	-1.37
Hypokalemia	4	3.78	2.64	1.43	-1.37

FIG. 27-40

Mycotoxin	4	3.13	2.18	1.43	-1.37
ELASTASE 2	4	3.76	2.63	1.43	-1.37
Ventricular Dysfunction	4	3.51	2.46	1.43	-1.37
Appendicitis	4	3.90	2.73	1.43	-1.37
PTHR1	4	2.16	1.51	1.43	-1.37
Quartz	4	3.23	2.27	1.42	-1.38
Myxoma	4	2.82	1.99	1.42	-1.38
BZRP	4	3.15	2.22	1.42	-1.38
Hypertriglyceridemia	4	3.65	2.57	1.42	-1.38
Blast Crisis	4	2.92	2.06	1.42	-1.38
Pepstatin	4	3.16	2.23	1.42	-1.38
Cytokinin	4	2.32	1.64	1.41	-1.39
Rabies	4	2.95	2.09	1.41	-1.39
Histiocytosis	4	3.15	2.23	1.41	-1.39
HFE	4	2.96	2.09	1.41	-1.39
alpha-Glucosidase	4	3.24	2.29	1.41	-1.39
Protein Precursors	4	3.06	2.17	1.41	-1.39
Hernia	4	3.39	2.41	1.41	-1.39
Ubiquinone	4	3.23	2.30	1.40	-1.40
Benzidine	4	3.20	2.28	1.40	-1.40
EIF2C2	4	3.38	2.41	1.40	-1.40
SICKLE CELL ANEMIA	4	3.31	2.36	1.40	-1.40
TRANSCRIPTION FACTOR 1	4	2.57	1.84	1.40	-1.40
Vindesine	4	2.40	1.72	1.40	-1.40
T-LYMPHOCYTE SURFACE CD2 ANTIGEN	4	2.71	1.94	1.40	-1.40
MTCYB	4	3.16	2.27	1.39	-1.41
Albuminuria	4	3.12	2.25	1.39	-1.41
Myristic Acid	4	2.73	1.96	1.39	-1.41
Pancreatic Insufficiency	4	3.08	2.22	1.39	-1.41
Codeine	4	3.23	2.33	1.39	-1.41
Thromboembolism	4	3.82	2.75	1.39	-1.41
Polynucleotide	4	2.95	2.13	1.39	-1.41
Cytidine	4	3.78	2.72	1.39	-1.41
Cholic Acid	4	3.22	2.32	1.39	-1.41
KNG	4	2.99	2.16	1.39	-1.41
Daunorubicin	4	3.65	2.64	1.39	-1.41
Metoclopramide	4	3.76	2.71	1.39	-1.41
Mineral Oil	4	2.92	2.11	1.38	-1.42
Erythema Nodosum	4	2.67	1.94	1.38	-1.42
Hydroquinone	4	3.37	2.46	1.37	-1.43
Tetanus Toxoid	4	3.23	2.37	1.37	-1.43
Uracil	4	3.81	2.79	1.37	-1.43
Chromosome Aberrations	4	3.82	2.80	1.37	-1.43
Insecticide	4	3.55	2.60	1.37	-1.43
Duodenal Ulcer	4	3.97	2.91	1.36	-1.44
Facies	4	3.15	2.31	1.36	-1.44
Ethane	4	2.81	2.06	1.36	-1.44
Thrombocytopenic Purpura	4	2.82	2.07	1.36	-1.44
Benzimidazole	4	3.05	2.24	1.36	-1.44
Catechol	4	3.83	2.81	1.36	-1.44
Aminoglutethimide	4	2.51	1.84	1.36	-1.44
Ribonucleotide	4	2.74	2.02	1.36	-1.44

FIG. 27-41

Ruthenium Red	4	3.48	2.56	1.36	-1.44
Doxycycline	4	3.93	2.89	1.36	-1.44
Homovanillic Acid	4	3.80	2.81	1.35	-1.45
Venous Thrombosis	4	3.98	2.95	1.35	-1.45
Carbodiimide	4	3.33	2.46	1.35	-1.45
Dimethylformamide	4	3.07	2.28	1.35	-1.45
Hypertrophic Cardiomyopathy	4	3.09	2.29	1.35	-1.45
Blister	4	3.22	2.39	1.35	-1.45
Glucose-6-Phosphatase	4	3.40	2.53	1.35	-1.45
Nucleoprotein	4	3.53	2.63	1.34	-1.46
IGBP1	4	3.13	2.33	1.34	-1.46
Glucoside	4	3.13	2.33	1.34	-1.46
AMYOTROPHIC LATERAL SCLEROSIS 1	4	3.77	2.80	1.34	-1.46
Galactosamine	4	3.30	2.46	1.34	-1.46
Gluten	4	2.82	2.10	1.34	-1.46
Urinary Incontinence	4	3.16	2.36	1.34	-1.46
Subtilisin	4	3.46	2.59	1.34	-1.46
CD19	4	3.12	2.33	1.34	-1.46
Alkalosis	4	3.23	2.42	1.33	-1.47
Miconazole	4	3.13	2.35	1.33	-1.47
Nicardipine	4	3.41	2.56	1.33	-1.47
Protein Deficiency	4	3.51	2.63	1.33	-1.47
Lactic Acidosis	4	3.33	2.50	1.33	-1.47
Purine Nucleotides	4	2.99	2.25	1.33	-1.47
Nitroglycerin	4	3.54	2.67	1.32	-1.48
Bronchogenic Carcinoma	4	2.82	2.13	1.32	-1.48
Cholate	4	3.09	2.34	1.32	-1.48
Enalapril	4	3.15	2.40	1.32	-1.48
Cannabinoid	4	2.80	2.13	1.32	-1.48
Fc Receptors	4	3.88	2.95	1.32	-1.48
Vertigo	4	3.51	2.66	1.32	-1.48
Iodoacetic Acid	4	2.81	2.14	1.31	-1.49
Inositol 1,4,5-Trisphosphate	4	3.47	2.65	1.31	-1.49
Cholecystitis	4	3.37	2.58	1.31	-1.49
Thrombophlebitis	4	3.15	2.41	1.31	-1.49
Tolbutamide	4	3.40	2.60	1.31	-1.49
Dipyridamole	4	3.99	3.06	1.31	-1.49
IRAK1	4	2.32	1.78	1.30	-1.50
Hydralazine	4	3.37	2.59	1.30	-1.50
ALPHA PROTEIN S	4	2.73	2.10	1.30	-1.50
Pyridoxal	4	3.40	2.62	1.30	-1.50
Palmitic Acid	4	3.72	2.86	1.30	-1.50
CD57	4	2.99	2.31	1.30	-1.50
Nimodipine	4	3.15	2.43	1.30	-1.50
Cardiac Glycosides	4	2.74	2.12	1.29	-1.51
Muscle Proteins	4	3.32	2.58	1.29	-1.51
Metyrapone	4	3.39	2.63	1.29	-1.51
GLUTATHIONURIA	4	3.55	2.76	1.29	-1.51
Periodontal Disease	4	3.50	2.73	1.28	-1.52
Aflatoxin B1	4	3.23	2.52	1.28	-1.52
Cyclophilin	4	2.56	2.00	1.28	-1.52
Dextran Sulfate	4	3.40	2.65	1.28	-1.52

FIG. 27-42

Dwarfism	4	3.74	2.92	1.28	-1.52
Dihydropyridine	4	3.72	2.90	1.28	-1.52
Polyvinyl Chloride	4	2.81	2.19	1.28	-1.52
ESSENTIAL HYPERTENSION	4	3.92	3.07	1.28	-1.52
Bronchiolitis	4	2.67	2.09	1.28	-1.52
Betamethasone	4	3.21	2.52	1.27	-1.53
Atenolol	4	3.34	2.63	1.27	-1.53
Coumarin	4	3.51	2.77	1.27	-1.53
Gliosid	4	3.92	3.12	1.26	-1.54
Pancuronium	4	2.71	2.16	1.26	-1.54
Pregnenolone	4	3.16	2.52	1.26	-1.54
Malate Dehydrogenase	4	3.15	2.52	1.25	-1.55
Diphtheria	4	2.67	2.13	1.25	-1.55
Carrageenan	4	3.13	2.50	1.25	-1.55
Cesium	4	3.16	2.52	1.25	-1.55
Polymyxin B	4	3.48	2.78	1.25	-1.55
Leprosy	4	3.45	2.76	1.25	-1.55
Fluorine	4	3.15	2.53	1.25	-1.55
Camptothecin	4	2.82	2.27	1.24	-1.56
Autolysis	4	3.16	2.55	1.24	-1.56
Capsaicin	4	3.65	2.96	1.23	-1.57
DOWN SYNDROME	4	3.78	3.06	1.23	-1.57
Naproxen	4	3.13	2.54	1.23	-1.57
NTS	4	3.16	2.57	1.23	-1.57
Antacid	4	2.32	1.89	1.23	-1.57
Dehydroepiandrosterone Sulfate	4	2.57	2.09	1.23	-1.57
Acetazolamide	4	3.40	2.78	1.22	-1.58
Prolapse	4	3.37	2.76	1.22	-1.58
Methyltransferase	4	3.58	2.94	1.22	-1.58
Thromboxane A2	4	4.00	3.29	1.22	-1.58
Syphilis	4	3.37	2.77	1.22	-1.58
CHOLELITHIASIS	4	3.41	2.81	1.21	-1.59
BRCA2	4	1.82	1.51	1.21	-1.59
Tetrachlorodibenzodioxin	4	2.96	2.45	1.21	-1.59
Lymphopenia	4	3.16	2.62	1.21	-1.59
Chest Pain	4	3.94	3.28	1.20	-1.60
Porphyrin	4	3.40	2.84	1.20	-1.60
Sitosterol	4	3.74	3.12	1.20	-1.60
Diclofenac	4	3.48	2.90	1.20	-1.60
Fluoxetine	4	2.99	2.50	1.20	-1.60
Oxygenase	4	3.48	2.92	1.19	-1.61
Propionic Acids	4	3.24	2.72	1.19	-1.61
Lipofuscin	4	2.81	2.36	1.19	-1.61
Tartrate	4	3.40	2.86	1.19	-1.61
Azide	4	3.76	3.17	1.19	-1.61
Sodium Salicylate	4	2.81	2.37	1.19	-1.61
Glaucoma	4	3.98	3.35	1.19	-1.61
Aminophylline	4	2.99	2.52	1.19	-1.61
Sulfonamide	4	3.81	3.23	1.18	-1.62
Carboplatin	4	2.83	2.40	1.18	-1.62
Kanamycin	4	3.37	2.86	1.18	-1.62
Maltose	4	3.37	2.87	1.17	-1.63

FIG. 27-43

Chagas Disease	4	3.33	2.84	1.17	-1.63
Drug Toxicity	4	3.16	2.70	1.17	-1.63
Diphosphonate	4	2.51	2.14	1.17	-1.63
Omithine	4	3.88	3.32	1.17	-1.63
Hyperbilirubinemia	4	3.09	2.65	1.17	-1.63
Gluconate	4	3.24	2.78	1.16	-1.64
Dinitrophenol	4	2.74	2.36	1.16	-1.64
Otitis Media	4	3.40	2.93	1.16	-1.64
alpha 1-Antitrypsin	4	3.41	2.94	1.16	-1.64
Immune Sera	4	3.32	2.88	1.15	-1.65
Reserpine	4	3.79	3.29	1.15	-1.65
Sinusitis	4	3.07	2.68	1.15	-1.65
Nicotinic Acids	4	2.98	2.61	1.14	-1.66
Mitoxantrone	4	2.58	2.26	1.14	-1.66
SHORT STATURE	4	3.62	3.18	1.14	-1.66
Leukocytosis	4	3.84	3.38	1.13	-1.67
TOP1	4	2.92	2.58	1.13	-1.67
Ligase	4	3.58	3.19	1.12	-1.68
Gynecomastia	4	2.16	1.93	1.12	-1.68
Digoxin	4	3.37	3.02	1.12	-1.68
Cadaver	4	3.13	2.82	1.11	-1.69
Guanosine Triphosphate	4	2.48	2.25	1.10	-1.70
Folic Acid	4	3.48	3.17	1.10	-1.70
Aluminum Hydroxide	4	2.56	2.34	1.10	-1.70
Borohydride	4	3.07	2.81	1.10	-1.70
Methane	4	2.91	2.66	1.09	-1.71
Splenomegaly	4	3.89	3.56	1.09	-1.71
SLC2A4	4	2.13	1.96	1.09	-1.71
Spontaneous Abortion	4	3.09	2.84	1.09	-1.71
Cerebral Infarction	4	3.16	2.94	1.08	-1.72
CP1	4	2.82	2.64	1.07	-1.73
Thiocyanate	4	3.06	2.86	1.07	-1.73
Diabetes Insipidus	4	2.58	2.42	1.07	-1.73
PARKINSON DISEASE	4	3.13	2.94	1.07	-1.73
MB	4	3.38	3.18	1.06	-1.74
Candidiasis	4	2.97	2.80	1.06	-1.74
Acrylamide	4	3.58	3.39	1.06	-1.74
Cholesterol Esters	4	2.67	2.54	1.05	-1.75
Muscle Weakness	4	3.55	3.38	1.05	-1.75
Taurine	4	3.57	3.40	1.05	-1.75
Memantine	4	2.74	2.62	1.05	-1.75
Ethylene	4	3.58	3.43	1.04	-1.76
Diltiazem	4	3.48	3.33	1.04	-1.76
Airway Obstruction	4	2.98	2.86	1.04	-1.76
Halothane	4	3.75	3.60	1.04	-1.76
Antiemetic	4	1.98	1.92	1.03	-1.77
Gamma-Globulin	4	3.84	3.73	1.03	-1.77
Benzene	4	3.72	3.63	1.03	-1.77
Pulmonary Edema	4	3.37	3.29	1.03	-1.77
Inulin	4	2.96	2.89	1.02	-1.78
Craniofacial	4	3.16	3.09	1.02	-1.78
Tritium	4	3.40	3.36	1.01	-1.79

FIG. 27-44

Tremor	4	3.54	3.49	1.01	-1.79
Dizziness	4	3.40	3.37	1.01	-1.79
Dermatitis	4	3.82	3.78	1.01	-1.79
Postoperative Complications	4	3.40	3.37	1.01	-1.79
Myocarditis	4	2.96	2.97	0.99	-1.81
Oxalate	4	2.99	3.01	0.99	-1.81
Aneurysm	4	3.55	3.58	0.99	-1.81
Amyloidosis	4	3.23	3.27	0.99	-1.81
Fistula	4	3.82	3.92	0.97	-1.83
Polyneuropathies	4	3.13	3.23	0.97	-1.83
Hypermethylation	4	2.00	2.07	0.97	-1.83
Guanylate Cyclase	4	2.82	2.93	0.96	-1.84
Benzodiazepine	4	3.65	3.84	0.95	-1.85
Overdose	4	3.40	3.58	0.95	-1.85
Levamisole	4	2.58	2.74	0.94	-1.86
CORTICOTROPIN-RELEASING HORMONE	4	2.55	2.71	0.94	-1.86
Arrhythmia	4	4.00	4.27	0.94	-1.86
Anesthetic	4	3.99	4.32	0.92	-1.88
Cystine	4	2.96	3.21	0.92	-1.88
Ifosfamide	4	2.16	2.41	0.90	-1.90
Abdominal Pain	4	3.96	4.42	0.90	-1.90
Calcium Chloride	4	2.32	2.64	0.88	-1.92
Sudden Death	4	2.98	3.43	0.87	-1.93
Mercury	4	3.40	3.98	0.85	-1.95
Hematoma	4	2.66	3.11	0.85	-1.95
Anorexia	4	3.57	4.19	0.85	-1.95
Hemolysis	4	3.58	4.25	0.84	-1.96
Haloperidol	4	2.89	3.49	0.83	-1.97
Enterotoxin	4	2.51	3.03	0.83	-1.97
Bicarbonate	4	3.56	4.47	0.80	-2.00
Hypotension	4	4.00	5.11	0.78	-2.02
Enkephalin	4	2.23	2.86	0.78	-2.02
Penicillin	4	3.12	4.04	0.77	-2.03
Potassium Channels	4	2.13	2.85	0.75	-2.05
Abscess	4	2.94	3.97	0.74	-2.06
Adrenergic Receptors	4	1.74	2.53	0.69	-2.11
Monoamine Oxidase	4	2.38	3.56	0.67	-2.13
Caffeine	4	3.00	4.49	0.67	-2.13
Jaundice	4	2.80	4.20	0.67	-2.13
Glutamate Receptors	4	2.13	3.23	0.66	-2.14
Dyspnea	4	2.51	4.02	0.62	-2.18
Phenylephrine	4	2.13	3.71	0.57	-2.23
Headache	4	2.79	5.07	0.55	-2.25

FIG. 27-45